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Abstract
With increased understanding of their roles in signal transduction and metabolism,
eicosanoids have emerged as important players in human health and disease. Mammalian
prostanoids and related lipid mediators perform varied functions in different tissues and organs.
Synthesized through the oxygenation of C20 polyunsaturated fatty acids, mammalian
eicosanoids are both pro- and anti-inflammatory. The physiological contexts in which eicosanoid
family members act at the cellular level are not well understood. In this study, we examined
whether the genome of Drosophila melanogaster, a powerful model for innate immunity and
inflammation, codes for the enzymes required for eicosanoid biosynthesis. We report the
existence of putative eicosanoid biosynthesis enzymes in Drosophila melanogaster which may
function together as a pathway similar to the mammalian eicosanoid synthesis pathway. Standard
sequence-based search methods failed to identify high confidence orthologs for a majority of the
mammalian eicosanoid synthesis enzymes in D. melanogaster, and in insects generally. Using
sensitive sequence analysis techniques, we identified candidate orthologs in the Drosophila
genome that share low global sequence identities with their human counterparts. The Drosophila
sequences were further scrutinized by modeling and structural analyses. We generated and
evaluated full-length models for top-scoring Drosophila candidates corresponding to each human
eicosanoid synthesis enzyme and identified potentially equivalent functional residues. This
combination of sensitive sequence and structural analyses revealed that the existence of eight
high confidence, five mid-range and eight low confidence candidates. Four predicted
cyclooxygenases and two potential lipoxygenase activating proteins, highly divergent from their
human counterparts, were identified, although similar methods failed to identify putative
lipoxygenase enzymes. Tertiary structures of a majority of identified candidate fly proteins are
very similar to the corresponding human target enzymes and appear to possess the necessary
iv

catalytic residues. These results, in combination with other recent biochemical studies alluding to
eicosanoid activity in insects by other groups, suggest that D. melanogaster may indeed possess
biosynthesis pathways for eicosanoid or eicosanoid-like biolipids. However, the predominant
view in the field is that an eicosanoid synthesis pathway does not exist in Drosophila primarily
because to date clear homologs of the enzymes of this pathway have not been identified. Our
study challenges this currently held view. Molecular-genetic and biochemical analyses of
individual biosynthetic enzymes in D. melanogaster, a model organism with low genetic
redundancy will reveal if the fly enzymes are functionally equivalent to their mammalian
counterparts; their in vivo interactions will allow construction of pathways and networks in a
physiological context. Our findings predict that classical or novel eicosanoids or eicosanoid-like
lipid mediators regulate biological functions in insects. Eicosanoids are known to play important
roles in insect immunity. The identification of these lipid mediators will therefore provide new
insect control measures or the means of improving the health of beneficial insects.
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superposition with conserved residues highlighted using the
CLUSTALX color scheme.
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Figure 65

Truncated CPA1 (2V77, cyan-blue) superimposed on the predicted
structure of CG18585 (green-red).
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Figure 66

Truncated CPA1 (2V77, cyan-blue) superimposed on the predicted
structure of CG18585 (green-red), with potential matches for
conserved functional residues highlighted.
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Figure 67

Predicted secondary structure of HPGDS and CG8938 calculated
using PROMALS3D.
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Figure 68

Predicted domain architecture of HPGDS and CG8938 determined
using Interpro and Pfam.

72

Figure 69

HMM profile of CG8938 aligned against chain A of 1IYH, a
template structure selected for modeling CG8938.
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Figure 70

Validation of the CG8938 model: ProQ2 quality score mapped to a
3D model of CG8938 (top); ProSA global quality score ranking
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(lower left) and per-residue quality graph (lower right).
Figure 71

Pairwise alignment of CG8938 and 1IYH generated from structural
superposition with shared secondary structure elements and
conserved residues highlighted.
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Figure 72

Pairwise alignment of CG8938 and 1IYH generated from structural
superposition with conserved residues highlighted using the
CLUSTALX color scheme.
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Figure 73

HPGDS (1IYH, cyan-blue) superimposed on the predicted structure
of CG8938 (green-red).
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Figure 74

HPGDS (1IYH, cyan-blue) superimposed on the predicted structure
of CG8938 (green-red), with potential matches for conserved
functional residues highlighted.
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Figure 75

Predicted secondary structure of PTGES3 and CG16817 calculated
using PROMALS3D.
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Figure 76

Predicted domain architecture of PTGES3 and CG16817
determined using Interpro and Pfam.
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Figure 77

HMM profile of CG16817 aligned against chain A of 1EJF, a
template structure selected for modeling CG16817.
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Figure 78

Validation of the CG16817 model: ProQ2 quality score mapped to a
3D model of CG16817 (top); ProSA global quality score ranking
(lower left) and per-residue quality graph (lower right).
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Figure 79

Pairwise alignment of CG16817 and 1EJF generated from structural
superposition with shared secondary structure elements and
conserved residues highlighted.
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Figure 80

Pairwise alignment of CG16817 and 1EJF generated from structural
superposition with conserved residues highlighted using the
CLUSTALX color scheme.
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Figure 81

PTGES3 (1EJF, cyan-blue) superimposed on the predicted structure
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Figure 82

PTGES3 (1EJF, cyan-blue) superimposed on the predicted structure
of CG16817 (green-red), with potential matches for conserved
functional residues highlighted.
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Figure 83

Predicted secondary structure of CBR1 and CG11200 calculated
using PROMALS3D.
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Figure 84

Predicted domain architecture of CBR1 and CG11200 determined
using Interpro and Pfam.
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Figure 85

HMM profile of CG11200 aligned against chain A of 3BHJ, a
template structure selected for modeling CG11200.
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Figure 86

Validation of the CG11200 model: ProQ2 quality score mapped to a
3D model of CG11200 (top); ProSA global quality score ranking
(lower left) and per-residue quality graph (lower right).
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Figure 87

Pairwise alignment of CG11200 and 3BHJ generated from
structural superposition with shared secondary structure elements
and conserved residues highlighted.
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Figure 88

Pairwise alignment of CG11200 and 3BHJ generated from
structural superposition with conserved residues highlighted using
the CLUSTALX color scheme.
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Figure 89

CBR1 (3BHJ, cyan-blue) superimposed on the predicted structure of
CG11200 (green-red).
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Figure 90

CBR1 (3BHJ, cyan-blue) superimposed on the predicted structure of
CG11200 (green-red), with potential matches for conserved
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89

Figure 91

Predicted secondary structure of HPGD and CG18814 calculated
using PROMALS3D.
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Figure 92

Predicted domain architecture of HPGD and CG18814 determined
using Interpro and Pfam.
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Figure 93

HMM profile of CG18814 aligned against chain A of 2GDZ, a
template structure selected for modeling CG18814.
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Figure 94

Validation of the CG18814 model: ProQ2 quality score mapped to a
3D model of CG18814 (top); ProSA global quality score ranking
(lower left) and per-residue quality graph (lower right).
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Figure 95

Pairwise alignment of CG18814 and 2GDZ generated from
structural superposition with shared secondary structure elements
and conserved residues highlighted.
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Figure 96

Pairwise alignment of CG18814 and 2GDZ generated from
structural superposition with conserved residues highlighted using
the CLUSTALX color scheme.
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Figure 97

HPGD (2GDZ, cyan-blue) superimposed on the predicted structure
of CG18814 (green-red).

95

xxiv

Figure 98

HPGD (2GDZ, cyan-blue) superimposed on the predicted structure
of CG18814 (green-red), with potential matches for conserved
functional residues highlighted.
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Figure 99

Predicted secondary structure of TBXAS1 and CG3616 calculated
using PROMALS3D.
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Figure 100

Predicted domain architecture of TBXAS1 and CG3616 determined
using Interpro and Pfam.
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Figure 101

HMM profile of CG3616 aligned against chain A of 4DGZ, a
template structure selected for modeling CG3616.
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Figure 102

Validation of the CG3616 model: ProQ2 quality score mapped to a
3D model of CG3616 (top); ProSA global quality score ranking
(lower left) and per-residue quality graph (lower right).
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Figure 103

Pairwise alignment of CG3616 and 4DGZ generated from structural
superposition with shared secondary structure elements and
conserved residues highlighted.
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Figure 104

Pairwise alignment of CG3616 and 4DGZ generated from structural
superposition with conserved residues highlighted using the
CLUSTALX color scheme.
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Figure 105

TBXAS1 (4DGZ, cyan-blue) superimposed on the predicted
structure of CG3616 (green-red).
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Figure 106

TBXAS1 (4DGZ, cyan-blue) superimposed on the predicted
structure of CG3616 (green-red), with potential matches for
conserved functional residues highlighted.
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Figure 107

Predicted secondary structure of PTGS1 and CG4009 calculated
using PROMALS3D.
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Figure 108

Predicted domain architecture of PTGS1 and CG4009 determined
using Interpro and Pfam.
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Figure 109

Multiple Sequence Alignment illustrating CG4009 aligned against
template structures selected by I-TASSER for multi-template
modeling of CG4009.
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Figure 110

Validation of the CG4009 model: ProQ2 quality score mapped to a
3D model of CG4009 (top); ProSA global quality score ranking
(lower left) and per-residue quality graph (lower right).
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Figure 111

Pairwise alignment of CG4009 and 3N8V generated from structural
superposition with shared secondary structure elements and
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conserved residues highlighted.
Figure 112

Pairwise alignment of CG4009 and 3N8V generated from structural
superposition with conserved residues highlighted using the
CLUSTALX color scheme.
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Figure 113

PTGS1 (3N8V, cyan-blue) superimposed on the predicted structure
of CG4009 (green-red).
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PTGS1 (3N8V, cyan-blue) superimposed on the predicted structure
of CG4009 (green-red), with potential matches for conserved
functional residues highlighted.
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Figure 115

Predicted secondary structure of PTGDS and CG33126 calculated
using PROMALS3D.
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Predicted domain architecture of PTGDS and CG33126 determined
using Interpro and Pfam.
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Figure 117

HMM profile of CG33126 aligned against chain A of 5WY9, a
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Figure 118

Validation of the CG33126 model: ProQ2 quality score mapped to a
3D model of CG33126 (top); ProSA global quality score ranking
(lower left) and per-residue quality graph (lower right).
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Figure 119

Pairwise alignment of CG33126 and 5WY9 generated from
structural superposition with shared secondary structure elements
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Figure 200

Pairwise alignment of CG33126 and 5WY9 generated from
structural superposition with conserved residues highlighted using
the CLUSTALX color scheme.
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Figure 201

PTGDS (5WY9, cyan-blue) superimposed on the predicted structure
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Figure 202

PTGDS (5WY9, cyan-blue) superimposed on the predicted structure
of CG33126 (green-red), with potential matches for conserved
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using PROMALS3D.
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Figure 204

Predicted domain architecture of PTGIS and CG3466 determined
using Interpro and Pfam.
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Figure 205

HMM profile of CG3466 aligned against chain A of 4DGZ, a
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template structure selected for modeling CG3466.
Figure 206

Validation of the CG3466 model: ProQ2 quality score mapped to a
3D model of CG3466 (top); ProSA global quality score ranking
(lower left) and per-residue quality graph (lower right).
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using PROMALS3D.
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Validation of the CG33178 model: ProQ2 quality score mapped to a
3D model of CG33178 (top); ProSA global quality score ranking
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Chapter 1: Introduction
Overview of the eicosanoid biosynthesis pathway
The eicosanoids are a family of biologically active lipids that have been implicated in
various signaling pathways, with a central role as mediators of inflammation [1-3]. The
canonical eicosanoid biosynthesis pathway begins with the release of fatty acids, primarily
arachidonic acid (AA), from membrane phospholipids in response to activation of phospholipase
A2 [4, 5]. At this point the canonical pathway diverges, depending on whether the fatty acid
substrate is processed by a cyclooxygenase (COX), lipoxygenase (LOX) or a P450 epoxygenase
(P450E). The COX enzymes generate prostanoids (prostaglandins, prostacyclins and
thromboxanes) and resolvins, whereas the LOX enzymes produce the leukotrienes,
hydroperoxyeicosatetraenoic acids (HPETEs), hydroxyeicosatetraenoic acids (HETEs) and
lipoxins. There is some cross-talk between the COX and LOX pathways, as both are known to
produce hydroxyoctadecadienoic acids (HODEs) The P450 epoxygenase pathway yields
epoxyeicosatrienoic acids (EETs). All these downstream products of the canonical eicosanoid
pathway branches regulate a diverse variety of signaling pathways, with the COX and LOX
subfamilies emerging as important mediators of inflammation and immunity in mammals [6-9].
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FIG. 1. The canonical human eicosanoid synthesis pathway. Prostaglandins are highlighted
in red, leukotrienes in green and thromboxanes in blue. HETE mediators, which form part
of the non-classic eicosanoid pathway, are highlighted in yellow.

The COX branch of the eicosanoid pathway
The COX and LOX branches of the eicosanoid pathway are well-characterized in
humans. The COX enzymes (prostaglandin G/H synthases) are encoded by two genes: COX-1
(PTGS1) and COX-2 (PTGS2) [10]. COX-1 is constitutively expressed at a low level by most
cells. In contrast, COX-2 is upregulated at sites of inflammation and during tumor progression
[10, 11]. COX-1 and COX-2 are membrane-associated heme-containing homodimers that
catalyze the conversion of an 18-22 carbon polyunsaturated fatty acid (typically AA, an ω-6, 20carbon fatty acid) into prostaglandins G2 and H2 [12]. Although AA is the preferred substrate,
and COX signaling tends to be pro-inflammatory, the COX enzymes are also known to
oxygenate eicosapentaenoic acid (EPA, 20:5 n-3), linoleic acid (LA, 18:2 n-6), dihomo-γlinolenic acid (DHLA) and docosahexaenoic acid (DHA), with varying efficiencies [12-14]. This
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initial substrate choice is significant, as it determines whether the downstream prostanoid will be
pro- or anti-inflammatory. Fatty acid with two double bonds (e.g., AA) are converted into series2 prostanoids (e.g., PGH2, PGE2), which are associated with pro-inflammatory signaling. In
contrast, fatty acid substrates with three or four double bonds (e.g., EPA, DHLA, respectively)
yield series-1 and 3 prostanoids (PGH1, PGE3), which are associated with anti-inflammatory
signaling. Anti-inflammatory resolvins are produced from EPA and DHA, whereas the pro- and
anti-inflammatory 9- and 13-HODEs are generated from LA by COX enzymes [15,16].
Non-steroidal anti-inflammatory drugs (NSAIDs) can inhibit the ability of COX enzymes to
generate pro-inflammatory downstream products [17]. PGH2 is subsequently converted to a
variety of downstream eicosanoids, including PGD2, PGE2, PGF1α PGF2α, PGI2 (prostacyclin),
and the thromboxanes TXA2 and TXB2. The downstream processing route depends on the
enzymatic machinery present in a given cell type. For example, endothelial cells primarily
produce PGI2, whereas platelets mainly produce TXA2 [18].

The LOX branch of the eicosanoid pathway
The LOX pathway operates independently from the COX pathway, diverging at the
initial fatty acid processing stage. In humans, LOX enzymes are encoded by several genes
(ALOX5, ALOX12, ALOX12B, ALOX15). Mammalian LOX enzymes catalyze the
stereospecific dehydrogenation and dioxygenation of a polyunsaturated fatty acid (PUFA),
leading to the formation of a hydroxyperoxide containing a 1-hydroxyperoxy-2-trans-4-cispentadiene fragment [19, 20]. The mammalian LOXs have been named according to the position
of the carbon at which the oxygen molecule is inserted into AA, the primary fatty acid substrate,
e.g., as 5-, 12-, or 15-LOX) [21]. The primary products are 5S-, 12S-, or 15S-HPETE, which can
be further reduced by glutathione peroxidase to hydroxy forms (5-, 12-, 15-HETE), respectively
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[21, 23]. 5-LOX is the only LOX that produces leukotrienes, and it is notable that its catalytic
activity requires the presence of a second protein referred to alternatively as Arachidonate 5Lipoxygenase Activating Protein (ALOX5AP) or Five-Lipoxygenase Activating Protein (FLAP),
though the precise function of FLAP is unknown at this time [19, 22]. Following the conversion
of a fatty acid (e.g., AA) into 5-HPETE, processing by 5-LOX and other downstream leukotriene
syntheses enzymes results in the formation of leukotrienes LTB4, LTC4, LTD4, and LTE4. The
leukotrienes are clinically significant, as they are implicated in the allergic response and
maintenance of chronic inflammation. 15-LOX (and to a lesser extent 5-LOX) produce the
lipoxins LXA and LXB [23].

Non-classic Eicosanoids
The cyclooxygenase and lipoxygenase branches of the eicosanoid synthesis pathway have
been thoroughly studied in human and other mammalian systems. As a result, the major end
products of these pathways (i.e., prostaglandins, thromboxanes and leukotrienes) are referred to
as canonical eicosanoids. However, in recent years additional classes of oxygenated PUFA
derivatives have been identified as minor or alternative products of the eicosanoid synthesis
pathways, including eoxins, hepoxilins, resolvins, lipoxins, epi-lipoxins, levuglandins,
oxoeicosanoids, hydroxyeicosatrienoic acids (HETEs), epoxyeicosatrienoic acids (EETs) and
endocannabinoids. Together, this group represents a large and growing family of lipid mediators
generally referred to as non-classic eicosanoids.
Eoxins are pro-inflammatory eicosanoids derived from arachidonic acid by arachidonate 15lipoxygenase (ALOX15) [24]. The eoxins derive their name from eosinophils, the cell type in
which they were originally discovered in abundance [25]. Eoxins resemble the cysteinyl
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leukotrienes produced by ALOX5 but have a different three-dimensional structure (i.e., eoxins
are 14,15-leukotriene analogs) and are generated by cells in response to different stimuli [26].
Hepoxilins are hydroxy-epoxy eicosanoids (epoxyalcohols) which contain both hydroxyl
and epoxy groups, the latter spanning the C11-C12 double bond, and unlike leukotrienes and
lipoxins, none of the double bonds are conjugated [27]. Hepoxilins are produced by the
epidermal subfamily of mammalian lipoxygenase enzymes ALOX12B and ALOXE3 (12-RLOX and eLOX-3, respectively), which are preferentially expressed in the skin and several other
epithelial tissues [28]. These enzymes act in concert to convert fatty acid substrates via RHPETEs to specific epoxyalcohol derivatives [29]. 12R-LOX and eLOX-3 are unique compared
to all other currently identified LOXs in that 12R-LOX is the only mammalian LOX that forms
products with R-chirality and eLOX-3 functions as a hydroperoxide isomerase by exhibiting only
latent dioxygenase activity [30].
Lipoxins, epi-lipoxins and resolvins are potent anti-inflammatory eicosanoids which
modulate the inflammation response in mammals. Lipoxins and epi-lipoxins (stereoisomers of
lipoxins) are derived from arachidonic acid and contain three hydroxyl residues and four double
bonds [31]. Lipoxins synthesis typically involves a LOX enzyme which adds a 15S-hydroxyl
residue to arachidonic acid, whereas synthesis of the epi-lipoxins involves aspirin-pretreated
COX-2 or a CYP450 enzyme capable of adding a 15R-hydroxyl residue to arachidonic acid [32].
Resolvins are a structurally diverse class of oxygenated derivatives of the omega-3 PUFAs
(EPA, DHA, DPA), which derive their name from the fact that this family of lipid mediators is
known to be produced during the resolution phase of the inflammation response [33, 34].
Levuglandins are reactive γ-ketoaldehydes formed by the spontaneous rearrangement of
prostaglandin H (PGH) [35, 36]. Levuglandins are highly effective at cross-linking proteins and
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DNA, which makes detection difficult as newly-produced levuglandins are rapidly sequestered
by available nucleophiles, potentially generating heterogeneous protein aggregates which may
have pathologic consequences if prostanoids are aberrantly overexpressed [35].
Oxo-eicosanoids refer to oxygenated derivatives of eicosatetraenoic acid (e.g., 5-Oxo6,8,11,14-eicosatetraenoic acid, “5-oxo-ETE”), which are produced by a dehydrogenase acting
on HETE intermediates produced by LOX enzymes [37]. Oxo-eicosanoids are known to produce
pro-inflammatory effects similar to leukotrienes, but interact with different cell surface receptors
[38, 39].
Epoxyeicosatrienoic acids (EETs) and hydroxyeicosatrienoic acids (HETEs) are derived
from arachidonic acid by a subset of CYP450 enzymes [40]. The CYP450 superfamily includes
various heme-containing enzymes that are essential for basic metabolism in humans and
ubiquitous among all five kingdoms of life [41]. In the context of eicosanoid synthesis, CYP450
enzymes are necessary for the synthesis of prostacyclins and thromboxanes (i.e., prostacyclin
synthase and thromboxane A synthase are both CYP450 family members) [42]. However,
CYP450 enzymes are further relevant to arachidonic acid metabolism given that two distinct
subfamilies (ω-hydroxylases and epoxygenases) are also able to form metabolites derived from
arachidonic acid [40, 43, 44]. Arachidonic acid is metabolized by the CYP450 ω-hydroxylase
family of enzymes in mammalian cells to 7-, 10-, 12-, 13-, 15-, 16-, 17-, 18-, 19-, and 20HETEs, with the pro-inflammatory 20-HETE being the primary metabolite [45]. In contrast, the
epoxygenase CYP450 enzymes metabolize arachidonic acid by olefin epoxidation, resulting in
four regioisomeric epoxyeicosatrienoic acids (EETs): 5,6-EET, 8,9-EET, 11,12-EET, and 14,15EET [46]. Each of these regioisomers can be formed as either an R,S or S,R enantiomer given
that the epoxide group can attach to the double bonds in two separate configurations [47].
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CYP450 enzymes also convert EPA into epoxy-derivatives, and endocannabinoids containing
11,12- and 14,15-EETs. [48].
The various non-classic eicosanoids discussed above includes clinically important
autocrine and paracrine mediators of inflammation and homeostasis that operate in parallel with
the classic eicosanoids.
Eicosanoid biosynthesis and signaling in insects
Extensive scientific literature from the last 25 years, based primarily in mammalian cell
culture and rodent models, has established the central roles of eicosanoids in the response to
infection (acute inflammation) as well as in chronic diseases in humans and various animal
models [47-49]. A number of vertebrate and cell culture models that mimic human diseases are
now available for studying inflammation. Despite an overwhelming increase in our knowledge
regarding mechanisms underlying inflammation, it has been difficult to genetically map the
signaling pathways targeted by eicosanoids. A primary reason for this gap is the large number of
prostanoids and lipid mediators and the complexity of the mammalian system itself.
In order to better understand the COX and LOX pathways, identification of suitable model
organisms is a priority. The COX family enzymes are highly conserved across the animal
kingdom, with orthologs found in the primitive marine corals as well as the higher vertebrates
[50]. Traditional genomic analyses have failed to identify COX orthologs in the known genomes
of insects, unicellular organisms, or plants, although prostaglandins, their primary products, have
been found in some of these organisms [51, 52]. Recent studies have suggested that an insect
cyclooxygenase may exist in orthologs of the gene Pxt [53, 54]. LOX enzymes display an even
broader degree of conservation, with orthologs found across the animal kingdom and in a variety
of plants [55]. Interestingly enough, sequence and biochemical analyses have failed to identify
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any insect LOX orthologs, with the sole exception being a report of LOX activity in the primitive
insect, Thermobia domestica [56].
As mediators of the immune and inflammatory response in mammals, eicosanoids remain
an important area of research. A better understanding of these enzymes (and their biosynthesis),
may yield therapeutics that mitigate inflammation or compensate for defects in the immune
response. The canonical eicosanoid synthesis pathway (prostanoids and leukotrienes) is wellcharacterized in humans and in mammalian models. However, researchers would benefit from
having access to a low cost, high volume model to study this pathway, i.e., D. melanogaster. In
order to better understand the in vivo roles of mammalian COX and LOX pathways, we
examined if enzymes of these pathways are encoded in the Drosophila genome. Flies do not
produce C20 PUFAs, but nevertheless possess the ability to produce lipid mediators [57]. While
an initial BLAST searches based on sequence analysis alone failed to identify likely fly orthologs
for these enzymes, a more rigorous approach using iterative sequence searches combined with
structural modeling revealed a surprising degree of similarity and apparent conservation of
catalytic as well as other key functional residues. Our study suggests that insects possess a
functional eicosanoid pathway and open up possibilities of utilizing a powerful model organism
for eicosanoid research.
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Chapter 2: Materials and Methods
Overview
The flowchart provided below summarizes the general protocol of the present study with
the various tools used to identify and characterize putative D. melanogaster eicosanoid synthesis
enzymes which may be orthologs for the classic eicosanoid synthesis enzymes discussed in detail
below.

FIG. 2. Summary of the workflow and tools used to carry out the present study.
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Selection and Characterization of Human Eicosanoid Synthesis Enzymes
A canonical eicosanoid synthesis pathway in humans was obtained from the NCBI
BioSystems Database by compiling enzymes identified in the Eicosanoid Synthesis (BSID:
198888) and Arachidonic Acid pathway maps (BSID: 829971) [58]. Protein sequence(s) for each
gene associated with the canonical human eicosanoid synthesis pathway were obtained from the
NCBI RefSeq database [59]. In each case, either the sole protein product or the major isoform
was selected as the representative sequence for each enzyme. Known and high-confidence
predicted orthologs for each of the canonical mammalian eicosanoid synthesis enzymes were
identified using the KEGG Orthology database [60]. A multiple sequence alignment (MSA) for
each target enzyme with the selected orthologs was then generated using PROMALS3D,
followed by manual refinement of the alignment [61]. Domains and active sites on each query
and putative D. melanogaster ortholog enzyme were annotated (or predicted, in the case of the
putative orthologs) using the Pfam and InterPro databases [62, 63]. Consensus secondary
structure profiles were generated using the PsiPred, JPred and PSSPred servers [64-66] to
confirm identified functional domains and to ascertain domain boundaries. The mammalian
eicosanoid synthesis enzymes selected as targets for this study are summarized by Table 1.
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TABLE 1. Summary of the mammalian eicosanoid synthesis enzymes selected as
representatives for this study.

NCBI Gene
Accession
(UniProt ID)
ALOX5
(P09917)
ALOX12
(P18054)
ALOX12B
(O75342)
ALOX15
(P16050)
ALOX5AP
(P20292)
LTA4H
(P09960)
LTC4S
(Q168730
GGT1
(P19440)
DPEP1
(P16444)
PTGS1
(P23219)
PTGS2
(P35354)
PTGDS
(P41222)
PTGIS
(Q16647)
PTGES
(O14684)
PTGES2
(Q9H7Z7)
PTGES3
(Q15185)
TBXAS1
(P24557)
AKR1C3
(P42330)
CBR1
(P16152)
HPGD
(P15428)

TABLE 1: Human Eicosanoid Synthesis Enzymes
NCBI Protein
RefSeq Accession
Common Name
(length)
NP_000689.1
Arachidonate 5(674 aa)
lipoxygenase
NP_000688.2
Arachidonate 12(663 aa)
lipoxygenase, S-type
NP_001130.1
Arachidonate 12R(701 aa)
lipoxygenase, R-type
NP_001131.3
Arachidonate 15(662 aa)
lipoxygenase
Arachidonate 5NP_001620.2
lipoxygenase Activating
(161 aa)
Protein
NP_000886.1
Leukotriene A4 hydrolase
(611 aa)
NP_665874.1
Leukotriene C4 synthase
(150 aa)
NP_001275762.1
Leukotriene C4 hydrolase
(569 aa)
NP_001121613.1
Dipeptidase 1
(411 aa)
NP_000953.2
Cyclooxygenase 1
(599 aa)
NP_000954.1
Cyclooxygenase 2
(604 aa)
NP_000945.3
Prostaglandin D synthase
(190 aa)
NP_000952.1
Prostacyclin synthase
(500 aa)
NP_004869.1
Microsomal prostaglandin
(152 aa)
E synthase 1
NP_079348.1
Microsomal prostaglandin
(377 aa)
E synthase 2
NP_006592.3
Cytosolic prostaglandin E
(160 aa)
synthase
NP_001052.2
Thromboxane A2 synthase
(534 aa)
NP_003730.4
Prostaglandin F synthase
(323 aa)
NP_001748.1
Carbonyl reductase 1
(277 aa)
NP_000851.2
15-hydroxyprostaglandin
(266 aa)
dehydrogenase NAD(+)
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Representative
Crystal
Structure
3O8Y
(2.39 Å)
3D3L
(2.60 Å)
None available.
2P0M
(2.40 Å)
2Q7M
(4.00 Å)
3CHO
(1.80 Å)
3PCV
(1.90 Å)
4GDX
(1.67 Å)
1ITQ
(2.30 Å)
1Q4G
(2.00 Å)
3NT1
(1.73 Å)
4IMO
(1.88 Å)
2IAG
(2.15 Å)
4AL0
(1.16 Å)
2PBJ
(2.80 Å)
1EJF
(2.49 Å)
None available.
1RY0
(1.69 Å)
3BHM
(1.80 Å)
2GDZ
(1.65 Å)

Identification of Potential Eicosanoid Synthesis Enzymes in D. melanogaster
We used several different sequence analysis algorithms to identify candidate Drosophila
orthologs for each human enzyme. Specifically, each human enzyme reference sequence was
queried against a subset of the D. melanogaster NCBI non-redundant sequence database using
PSI-BLAST, DELTA-BLAST or JACKHMMER [67-69]. DELTA-BLAST is a more sensitive
variant of the traditional BLAST algorithm that incorporates domain information from preconstructed position specific scoring matrices (PSSMs) in order to improve detection of
homology. JACKHMMER is an alternative sequence analysis and alignment tool that relies on
hidden Markov model (HMM) profiles in order to boost sensitivity compared to the traditional
BLAST algorithms. JACKHMMER converts a query sequence into a HMM profile using a
substitution matrix and gap penalties, which is then searches against a sequence database (e.g.,
the NCBI refseq database). Sequences that score above the inclusion threshold from this first
search are then aligned and used to construct a second HMM profile, which may then be queried
once again against the same database [70]. The iterative nature of this filtering process typically
results in a HMM profile that is able to detect distant homologs that may not be detected by the
traditional BLAST algorithms. For this study, BLAST and HMMer algorithms were leveraged as
part of a combined approach in order to identify candidates which may be remote homologs for
the human eicosanoid synthesis enzymes.
Each search was conducted with three iterations using the default parameters. D.
melanogaster candidates with statistically significant full-length alignments to the query were
selected after each round. These candidates were then analyzed using the same secondary
structure and domain analysis tools as discussed in the section above. Each candidate was then
aligned against the previously generated MSA (containing the human enzyme and

12

known/predicted orthologs) in order to screen out hits that lacked known functional residues
and/or those with substantially dissimilar secondary structure or domain architecture.
In silico Modeling of D. melanogaster Candidates
Full-length three-dimensional models were generated for each top-scoring D.
melanogaster candidate protein identified in the previous stage using the MODELLER,
LOMETS and I-TASSER software packages [71-73]. MODELLER, a homology modeling tool,
predicts the tertiary structure of a protein sequence based on satisfaction of spatial restraints
derived from sequentially similar templates whose structure is known (i.e., a sequence-sequence
comparison). In contrast, I-TASSER utilizes a threading algorithm (i.e., a sequence-structure
comparison) and fragment assembly based on replica-exchange Monte Carlo simulations; it also
builds unaligned primary sequence regions using ab initio methods. LOMETS is a meta-server
that generates and ranks modeling results produced using several alternative threading
algorithms which are executed in parallel. The accuracy of homology modeling depends largely
on the target-template alignment, with ≥40% sequence identity generally yielding high quality
models and ≥30% being the lower threshold for an acceptable model [74]. However, threading
based modeling tools are generally less sensitive to sequence identity differences and some
packages (e.g., I-TASSER) are known to generate high quality models using templates sharing as
little as 20-30% sequence identity with the target sequence [75, 76].
Each D. melanogaster candidate sequence was searched against the Protein Data Bank
database of published structures using PSI-BLAST and JACKHMMER [67, 69]. Several
potential templates with ≥30%, full-length sequence identity were aligned against each candidate
using PROMALS3D and evaluated [61]. In instances where a single full-length template was
available, MODELLER was used to generate a three-dimensional model of the candidate. If a
13

suitable single full-length template was not found, either due to a lack of coverage or low
sequence identity within the aligned range, I-TASSER was used to generate a composite model
based on several templates. In each case, the initial model was used to generate a refined full
atomic model using ModRefiner, which also optimizes sidechain placement [77]. All of the
refined models were then evaluated using the PROCHECK, ProSa, ProQ2 and MODFOLD4
servers [78-80]. Loops and unstructured N- and C-terminal regions in these models were
optimized using ab initio methods (e.g., MODELLER’s loop routines or QUARK), refined using
ModRefiner and reevaluated as necessary [81]. Unsuitable models were rejected and rebuilt
using alternatives templates according to the preceding protocol. Models were analyzed using the
surface property tools in the Chimera and PyMol visualization and structural modeling packages,
in addition to online tools including, COFACTOR, and COACH [82-87].
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Chapter 3: Results
Identification and Characterization of Candidate Eicosanoid Synthesis Enzymes in D.
melanogaster
A purely sequence-based analysis of the D. melanogaster genome (Release 6.04,
February 24th, 2015) using traditional sequence analysis tools (e.g., BLASTp) fails to identify
likely orthologs for a majority of the canonical human eicosanoid synthesis enzymes. However,
using a more sensitive approach based on iterative HMMER searches and structural modeling,
we have uncovered potential candidates in D. melanogaster that may function as eicosanoid
synthesis enzymes. This analysis is supported by the fact that a majority of these candidates
share a highly similar tertiary structure with the human target enzymes and also appear to
possess the necessary catalytic residues. A summary of our findings is provided as Table 2.
TABLE 2. Summary of D. melanogaster genes encoding potential orthologs for the
mammalian eicosanoid synthesis enzymes examined during this study.
TABLE 2: Summary of Findings
Human
Gene
PTGS1,
PTGS2
PTGDS
HPGDS
PTGIS
PTGES
PTGES2
PTGES3
TBXAS1
AKR1A1,
AKR1B1,
AKR1C3
CBR1

CG
Identifier
CG4009
CG7660
CG6969
CG33126
CG8938
CG3466

Flybase
Identifier
FBgn0038469
FBgn0261987
FBgn0263986
FBgn0053126
FBgn0010226
FBgn0011576

CG1742

FBgn0025814

CG4086
CG16817
CG17577

FBgn0004465
FBgn0037728
FBgn0033775

CG6084, isoform D

CG6084

FBgn0086254

CBR, isoform B (“carbonyl reductase”)

CG11200

FBgn0034500

D. melanogaster Candidate(s)
CG4009, isoform B
Pxt (“Peroxinectin-like”)
Cardinal
Nlaz (“Neural Lazarillo”)
GST S1 (“Glutathione S transferase S1”)
CYP450-4D2
MGST-like, isoform A (“microsomal
glutathione S-transferase-like”)
SupRef(2)p [“Suppressor of Ref(2)p”]
CG16817, isoform A
CYP450-9H1
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ALOX5,
ALOX12,
ALOX12B,
ALOX15
ALOX5AP
LTA4H
LTC4S
GGT1
DPEP1
HPGD
GPX1
CPA1

None identified

N/A

N/A

CG33177
CG10602
CG33178, isoform A
GGT, isoform A (“gamma-glutamyl
transpeptidase”)
CG6154, isoform C
CG18814
PHGPx, isoform A
CG18585, isoform A

CG33177
CG10602
CG33178

FBgn0053177
FBgn0032721
FBgn0053178

CG6461

FBgn0030932

CG6154
CG18814
CG12013
CG18585

FBgn0039420
FBgn0042137
FBgn0035438
FBgn0031929

Group 1: The High Scoring Matches
Eight of the putative orthologs identified in this search are notable for being particularly
high confidence matches: CG1742, CG4086, CG6084, CG10602, CG6461, CG6154, CG12013
and CG18585. Members of this set share a minimum of 30% sequence identity with the human
enzyme, the same overall fold, and display conservation of one or more functional residues.
Prostaglandin E Synthase (PTGES)
The first gene in this set, CG1742 (“MGST-like, isoform A,” NP_524696.1), encodes a
152 amino acid protein predicted to have a single pfam domain (MAPEG, PF01124) spanning
the 18 to 148 amino acid region. This protein displays 34% identity and 53% similarity to the
sequence of human prostaglandin E synthase (PTGES, NP_004869.1). PTGES is an integral
membrane protein that operates as a homotrimer, and is known to catalyze the oxidoreduction of
prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2). PTGES is also characterized
by the presence of a single MAPEG domain, which spans the region 16-146. PTGES (e.g., PDB
4AL0). The predicted structure of CG1742 are nearly identical and display an RMSD 1.15 Å
when superimposed, as shown in Fig. 9 below.
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PTGES is a glutathione-binding protein, and residues R38, R70, E77, R110, Y117, R126, and
Y130 are associated with this activity [88]. Structural superposition reveals that CG1742 has an
aligned match for each of these residues, R40, R71, E78, R111, Y118, R128 and F132. With
respect to the last residues, a tyrosine to phenylalanine substitution is likely to be functionally
equivalent as phenylalanine and tyrosine have side chains with a single aromatic ring of similar
volume. Phenylalanine differs only in that it lacks the hydroxyl group in the ortho position on the
benzene ring. Previous studies report that the aromatic ring of Y130 is likely important for
PGH2-binding and an analog for this structural element is provided by F132 [89].
A. Predicted Secondary Structure

FIG. 3. Predicted secondary structure of PTGES and CG1742 calculated using
PROMALS3D.
B. Domain Architecture

FIG. 4. Predicted domain architecture of PTGES and CG1742 determined using Interpro
and Pfam.
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C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG1742. All three tools identify chain A of 4YL0 (human prostaglandin E synthase) as a highscoring match suitable for single-template modeling.
CG1742 Range
4-151

Template Range
2-149

% Identity
36%

% Similarity
58%

E-Value
5.3e-22

FIG. 5. HMM profile of CG1742 aligned against chain A of 4YL0, a template structure
selected for modeling CG1742.
2. Validation
The quality of the CG1742 model was evaluated using ProQ2 and ProSA. The per
residue S-Score plot generated by ProQ2 was mapped to the CG1742 model by saving the SScore assigned to each residue as a B-factor field parameter and then rendering a color-coded
ribbon view in Chimera based upon this parameter. As illustrated by the image below, overall
model quality following refinement is high. The quality of the CG1742 model was also evaluated
using ProSA and found to display a quality level comparable to experimentally determined
structures having a comparable length (i.e., a global Z-score of -4.07). The ProSA per-residue
energy score graph is also favorable, showing a score that is consistently negative over a window
size of 40 residues.
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Knowledge-based Energy

Position
FIG. 6. Validation of the CG1742 model: ProQ2 quality score mapped to a 3D model of
CG1742 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
D. Structural Analyses
A structural superposition reveals that the CG1742 model and human prostaglandin E
synthase (4AL0) display a similar secondary structure architecture with substantial full-length
overlap. The pairwise alignment generated by this structural superposition also indicates
conservation of residues having similar physiochemical properties.

19

1. Secondary Structure

FIG. 7. Pairwise alignment of CG1742 and 4AL0 generated from structural superposition
with shared secondary structure elements and conserved residues highlighted.
2. Physiochemical Properties

FIG. 8. Pairwise alignment of CG1742 and 4AL0 generated from structural superposition
with conserved residues highlighted using the CLUSTALX color scheme.
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E. Analysis of Functional Residues

PTGES (PDB: 4AL0) and CG1742 Model
D. melanogaster
PTGES Structure
Superimposed
Model

FIG. 9. PTGES (4AL0, cyan-blue) superimposed on the predicted
structure of CG1742 (green-red). RMSD: 1.015 Å.

PTGES (PDB: 4AL0) and CG1742 Model Superimposed

FIG. 10. PTGES (4AL0, cyan-blue) superimposed on the predicted structure
of CG1742 (green-red), with potential matches for conserved functional
residues highlighted.
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F. Summary Table
TABLE 3. Summary of features shared by PTGES and potential D. melanogaster ortholog
CG1742.
Length
(AA)

Domain
Architecture
(Pfam, range)

Prostaglandin-E-synthase
(PTGES, NP_004869.1,
PDB: 4AL0)

152

MAPEG (PF01124)
16-146

MGST-like
(CG1742, NP_524696.1)

152

MAPEG (PF01124)
18-148

Functional Residues
(aligned matches in
D. melanogaster)
R38, E77, R70,
R110, Y117, R126,
Y130
R40, E78, R71,
R111, Y118, R128,
F132

Sequence
ID%

Structural
Overlap
(RMSD)

34% ID
53% SIM

1.015 Å

Prostaglandin Synthase E 2 (PTGES2)
The second gene in this set, CG4086 (“Su(P) Suppressor of ref(2)P sterility,”
NP_524116.2) encodes a 417 amino acid protein. CG4086 displays 33% identity and 49%
similarity to the sequence of human prostaglandin E synthase 2 (PTGES2, NP_079348.1).
PTGES2 is membrane-associated, as opposed to PTGES which is an integral membrane protein,
though both catalyze the same reaction. Despite the functional similarities, PTGES2 possesses a
substantially different domain architecture and tertiary structure. PTGES2 possesses GST
domains (PF13417 and PF14497) spanning amino acids 104-175 and amino acids 201-368.
CG4086 shares a highly similar domain architecture with a Glutaredoxin domain (PF00462),
which is functionally related to the GST domain, spanning amino acids 125-184 and a GST
domain (PF14497) spanning amino acids 248-396. PTGES2’s catalytic activity requires C110
[90]. The crystal structure of truncated PTGES2 has been published (1Z9H), with the N-terminal
membrane-associated region omitted (residues 1 to 99). Superposition of this truncated structure
against the predicted structure of CG4086 reveals an RMSD of 0.814 Å. CG4086’s C133
overlaps with PTGES2’s C110, suggesting a match for this catalytic residue.
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A. Predicted Secondary Structure

FIG. 11. Predicted secondary structure of PTGES2 and CG4086 calculated using
PROMALS3D.
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B. Domain Architecture

FIG. 12. Predicted domain architecture of PTGES2 and CG4086 determined using
Interpro and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG4086. All three tools identify chain A of 1Z9H (Macaca fascicularis prostaglandin E
synthase-2) as a high-scoring match suitable for single-template modeling. The human and M.
fascicularis orthologs of prostaglandin E synthase-2 are membrane-bound enzymes with a short
N-terminal transmembrane domain. The cytosolic portion of M. fascicularis prostaglandin E
synthase-2 begins at approximately position 80 of the full-length sequence and includes the
remainder of the protein. The 1Z9H structure provides data for the majority of this cytosolic
domain (i.e., 100-373) of the full-length M. fascicularis prostaglandin E synthase-2 sequence.
The cytosolic domain of M. fascicularis prostaglandin E synthase-2 is identified as a template
suitable for modeling 120-397 of the CG4086 sequence. The N-terminus of CG4086 is predicted
to have a transmembrane or membrane-associated region, suggesting a similar shared
architecture compared to human and M. fascicularis prostaglandin E synthase-2.
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CG4086 Range
120-397

Template Range
3-288

% Identity
44%

% Similarity
65%

E-Value
1.1e-71

FIG. 13. HMM profile of CG4086 aligned against chain A of 1Z9H, a template structured
selected for modeling CG4086.
2. Validation
The quality of the CG4086 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -6.52). The ProSA per-residue energy score graph is also favorable, showing a score that is
consistently negative over a window size of 40 residues. The N-terminal region of the model is
indicated to have a comparatively low quality. However, this may be explained by the fact that
this segment connects to the predicted transmembrane or membrane-associated N-terminal
domain which was for which no suitable template exists at this time. The N-terminal segment
may be a disordered linker to the membrane-bound/associated N-terminus. In any event, this
segment cannot be reliably modeled using existing homology or ab initio methods.
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Knowledge-based Energy

Position
FIG. 14. Validation of the CG4086 model: ProQ2 quality score mapped to a 3D model of
CG4086 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
D. Structural Analyses
A structural superposition reveals that the CG4086 model and M. fascicularis
prostaglandin E synthase-2 (1Z9H) display a similar secondary structure architecture across the
modeled region with substantial full-length overlap. The pairwise alignment generated by this
structural superposition also indicates substantial conservation of residues having similar
physiochemical properties.
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1. Secondary Structure

FIG. 15. Pairwise alignment of CG4086 and 1Z9H generated from structural superposition
with shared secondary structure elements and conserved residues highlighted.
1. Physiochemical Properties
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FIG. 16. Pairwise alignment of CG4086 and 1Z9H generated from structural superposition
with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

PTGES2 (PDB: 1Z9H) and CG4086 Model
D. melanogaster
PTGES Structure
Superimposed
Model

FIG. 17. Truncated PTGES2 (1Z9H, cyan-blue) superimposed on the predicted
structure of CG4086 (green-red). RMSD: 0.814 Å.
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PTGES2 (PDB: 1Z9H) and CG4086 Model Superimposed

FIG. 18. Truncated PTGES2 (1Z9H, cyan-blue) superimposed on the
predicted structure of CG4086 (green-red), with potential matches for
conserved functional residues highlighted.
F. Summary Table
TABLE 4. Summary of features shared by PTGES2 and potential D. melanogaster ortholog
CG4086.
Length
(AA)
Prostaglandin-E-synthase 2
(PTGES2, NP_079348.1,
PDB: 1Z9H)

Suppressor of ref(2)P
sterility
(CG4086, NP_524116.2)

377

417

Domain
Architecture
(Pfam, range)
GST-N3 domain
(PF13417)
104-175
GST-C3 (PF14497)
201-368
Glutaredoxin domain
(PF00462)
125-184
GST-C domain
(PF14497)
248-396
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Functional Residues
(aligned matches in
D. melanogaster)

Sequence
ID%

Structural
Overlap
(RMSD)

33% ID
49% SIM

0.814 Å

C110

C133

AKR1A1
The third gene in this set, CG6084, encodes a 316 amino acid protein that is a high
confidence match for the human AKR1A1 [“alcohol dehydrogenase NADP(+),” NP_001619.1].
This enzyme, along with enzymes encoded by the related genes in this family (e.g., AKR1B5
and AKR1C3), catalyzes the NADPH-dependent reduction of a variety of aromatic and aliphatic
aldehydes to their corresponding alcohols. In particular, AKR1B1 and AKR1B5 are known to
function as prostacyclin F synthases, converting prostaglandin endoperoxide H2 (PGH2) to
prostaglandin F2α (PGF2α) [91]. CG6084 and AKR1A1 share identical domain architectures [a
single aldo/keto reductase family (PF00248) domain], as well as 48% identity and 62% similarity
at the sequence level. AKR1A1 function requires the presence of three residues for its catalytic
activity, Y49, K78 and H111 [92]. CG6084 possesses analogs for this triad of residues in the
form of Y50, K79 and H112. In addition, the structural overlap of the predicted structure for
CG6084 and human AKR1A1 displays an RMSD of 0.847 Å.
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A. Predicted Secondary Structure

FIG. 19. Predicted secondary structure of AKR1A1 and CG6084 calculated using
PROMALS3D.
B. Function/Domain Analysis

FIG. 20. Predicted domain architecture of AKR1A1 and CG6084 determined using
Interpro and Pfam.
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C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG6084. All three tools identify chain A of 2ALR (human aldehyde reductase, AKR1A1) as a
high-scoring match suitable for single-template modeling.
CG6084 Range
6-316

Template Range
5-324

% Identity
51%

% Similarity
73%

E-Value
1.3e-98

FIG. 21. HMM profile of CG6084 aligned against chain A of 2ALR, a template structure
selected for modeling CG6084.
2. Validation
The quality of the CG6084 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
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of -10.94). The ProSA per-residue energy score graph is also favorable, showing a score that is

Knowledge-based Energy

consistently negative over a window size of 40 residues.

Position
FIG. 22. Validation of the CG6084 model: ProQ2 quality score mapped to a 3D model of
CG6084 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
D. Structural Analyses
A structural superposition reveals that the CG6084 model and human aldehyde reductase
(2ALR) display a similar secondary structure architecture across the modeled region with
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substantial full-length overlap. The pairwise alignment generated by this structural superposition
also indicates substantial conservation of residues having similar physiochemical properties.
1. Secondary Structure

FIG. 23. Pairwise alignment of CG6084 and 2ALR generated from structural superposition
with shared secondary structure elements and conserved residues highlighted.
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2. Physiochemical Properties

FIG. 24. Pairwise alignment of CG6084 and 2ALR generated from structural superposition
with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

AKR1A1 (PDB: 2ALR) and CG6084 Model
D. melanogaster
AKR1A1 Structure
Superimposed
Model

FIG. 25. AKR1A1 (2ALR, cyan-blue) superimposed on the predicted structure of CG6084
(green-red). RMSD: 0.847 Å.
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AKR1A1 (PDB: 2ALR) and CG6084 Model Superimposed

FIG. 26. AKR1A1 (2ALR, cyan-blue) superimposed on the predicted
structure of CG6084 (green-red), with potential matches for conserved
functional residues highlighted.
F. Summary Table
TABLE 5. Summary of features shared by AKR1A1 and potential D. melanogaster
ortholog CG6084.
Length
(AA)
Prostacyclin F synthase
(AKR1B1, NP_001619.1,
PDB: 1RY0)

316

Uncharacterized protein
(CG6084, NP_648484.1)

316

Domain
Architecture
(Pfam, range)
Aldo/keto reductase
family (PF00248)
4-289
Aldo/keto reductase
family (PF00248)
9-282

Functional Residues
(aligned matches in
D. melanogaster)
Y49, K78, H111
Y50, K79, H112

Sequence
ID%

Structural
Overlap
(RMSD)

48% ID
62% SIM

0.847 Å

LTA4H
The fourth gene in this set, CG10602 encodes a 613 amino acid protein that displays 44%
identity and 58% similarity to human leukotriene A4 hydrolase (LTA4H, NP_000886.1).
LTA4H is an epoxide hydrolase that catalyzes the hydrolysis of the epoxide LTA4 to the diol,
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LTB4. This catalytic activity requires the presence of a zinc ion, which is coordinated by the
catalytic triad of H296, H300 and E319. Residues E297, D376 and Y384 are also reportedly
essential for efficient catalysis [93]. LTA4H’s domain architecture consists of Peptidase family
M1 (PF01433) spanning 13-387 and a Leukotriene A4 hydrolase, C-terminal domain (PF09127)
spanning amino acids 464-608. CG10602 shares an identical domain organization as well as the
critical residues at H293, H297, E316 (the zinc triad) and E294, D374 and Y382. The tertiary
structure similarity is readily apparent, as evidenced by a superposition of human LTA4H
(1H19) and the predicted stature of CG10602, which results in an RMSD of 0.891 Å.
A. Predicted Secondary Structure

FIG. 27. Predicted secondary structure of LTA4H and CG10602 calculated using
PROMALS3D.
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B. Domain Architecture

FIG. 28. Predicted domain architecture of LTA4H and CG10602 determined using
Interpro and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG10602. All three tools identify chain X of 3B7U (human leukotriene A4 hydrolase) as a highscoring match suitable for single-template modeling.
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CG10602 Range
6-611

Template Range
9-614

% Identity
45%

% Similarity
66%

E-Value
4.1e-164

FIG. 29. HMM profile of CG10602 aligned against chain X of 3B7U, a template structure
selected for modeling CG10602.
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2. Validation
The quality of the CG10602 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -9.42). The ProSA per-residue energy score graph is also favorable, showing a score that is
consistently negative over a window size of 40 residues, except for minor high-energy regions at

Knowledge-based Energy

the N-terminus and two loop regions.

Position
FIG. 30. Validation of the CG10602 model: ProQ2 quality score mapped to a 3D model of
CG10602 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
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D. Structural Analyses
A structural superposition reveals that the CG10602 model and human leukotriene
hydrolase (3B7U) display a similar secondary structure architecture across the modeled region
with substantial full-length overlap. The pairwise alignment generated by this structural
superposition also indicates substantial conservation of residues having similar physiochemical
properties.
1. Secondary Structure
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FIG. 31. Pairwise alignment of CG10602 and 3B7U generated from structural
superposition with secondary structure elements and conserved residues highlighted.
2. Physiochemical Properties

FIG. 32. Pairwise alignment of CG10602 and 3B7U generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

LTA4H (PDB: 1H19) and CG10602 Model
D. melanogaster
LTA4H Structure
Superimposed
Model

FIG. 33. LTA4H (3B7U, cyan-blue) superimposed on the predicted
structure of CG10602 (green-red). RMSD: 0.891 Å.
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LTA4H (PDB: 3B7U) and CG10602 Model Superimposed

FIG. 34. LTA4H (3B7U, cyan-blue) superimposed on the predicted
structure of CG10602 (green-red), with potential matches for conserved
functional residues highlighted.
F. Summary Table
TABLE 6. Summary of features shared by LTA4H and potential D. melanogaster ortholog
CG10602.
Length
(AA)
Leukotriene A4
hydrolase
(LTA4H, NP_000886.1,
PDB: 1H19)

Uncharacterized protein
(CG10602,
NP_724139.1)

611

613

Domain
Architecture
(Pfam, range)
Peptidase family M1
(PF01433)
13-387
LTA4H, C-term (PF09127)
464-608
Peptidase family M1
(PF01433)
8-420
LTA4H, C-term (PF09127)
464-610
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Functional Residues
(aligned matches in
D. melanogaster)

Sequence
ID%

Structural
Overlap
(RMSD)

44% ID
58% SIM

0.891 Å

H296, E297, H300,
E319, D376 and
Y384

H293, E294, H297,
E316, D374 and
Y382

GGT1
The fifth gene in this set, CG6461, encodes a 579 amino acid protein (“Gammaglutamyltranspeptidase,” NP_573303.1) that shares 39% identity and 54% similarity to human
Gamma-glutamyltranspeptidase 1 (GGT1, NP_001275762.1). GGT1 cleaves the gammaglutamyl bond of extracellular glutathione (gamma-Glu-Cys-Gly), glutathione conjugates, and
other gamma-glutamyl compounds. With respect to eicosanoid synthesis, GGT1 catalyzes the
conversion of leukotriene C4 (LTC4) to leukotriene D4 (LTD4). GGT1 operates as a
heterodimer consisting of small and large subunits which are produced from the same precursor
that undergoes autocatalytic cleavage to produce the mature form of the enzyme. The only
reported catalytic residue is T381, which corresponds to T382 in CG6461. GGT1 residues R107,
T399 and E420 are believed to play a role in glutamate binding [94]. CG6461 possesses putative
analogs for each of these residues, namely R107, T400 and E421, respectively. CG6461 and
GGT1 also share identical domain architecture, with Gamma-glutamyltranspeptidase (PF01019)
domains spanning the majority of each protein. Superimposed, the human structure (4GDX) and
CG6461’s predicted structure display an RMSD of 1.126 Å.
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A. Predicted Secondary Structure

FIG. 35. Predicted secondary structure of GGT1 and CG6461 calculated using
PROMALS3D.
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B. Domain Architecture

FIG. 36. Predicted domain architecture of GGT1 and CG6461 determined using Interpro
and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG6461. All three tools identify chains A and B of 4GDX (human gammaglutamyltranspeptidase 1 heavy and light chains, respectively) as high-scoring matches suitable
for composite modeling. Human gamma-glutamyltranspeptidase 1 is expressed as a single
polypeptide which is cleaved during post-translational processing to produce a heavy chain and a
light chain which form the GGT1 holoenzyme complex. Chains A and B of the 4GDX PDB were
joined using Chimera to form a single composite structure which was then used as a single
template to model CG6461.
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CG6461 Range
7-370

Template Range
3-369 (Chain A)

% Identity
44%

% Similarity
59%

378-548

3-170 (Chain B)

52%

71%

E-Value
7.0e-69

1.6e-47

FIG. 37. HMM profile of CG6461 aligned against chains A and B of 4GDX, a template
structure selected for modeling CG6461.
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2. Validation
The quality of the CG6461 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG10602. Again, overall model quality is high (a ProSA global Zscore of -9.54). The ProSA per-residue energy score graph is also favorable, showing a score that

Knowledge-based Energy

is consistently negative over a window size of 40 residues.

Position
FIG. 38. Validation of the CG6461 model: ProQ2 quality score mapped to a 3D model of
CG6461 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
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D. Structural Analyses
A structural superposition reveals that the CG6461 model and human gammaglutamyltranspeptidase 1 (4GDX) display a similar secondary structure architecture across the
modeled region with substantial full-length overlap. The pairwise alignment generated by this
structural superposition also indicates substantial conservation of residues having similar
physiochemical properties.
1. Secondary Structure
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FIG. 39. Pairwise alignment of CG6461 and 4GDX generated from structural
superposition with secondary structure elements and conserved residues highlighted.
2. Physiochemical Properties

FIG. 40. Pairwise alignment of CG6461 and 4GDX generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

GGT1 (PDB: 4GDX) and CG6461 Model
GGT1 Structure

D. melanogaster
Model

Superimposed

FIG. 41. GGT1 (4GDX, cyan-blue) superimposed on the predicted structure of
CG6461 (green-red). RMSD: 1.126 Å.
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GGT1 (PDB: 4GDX) and CG6461 Model Superimposed

FIG. 42. GGT1 (4GDX, cyan-blue) superimposed on the predicted structure
of CG6461 (green-red), with potential matches for conserved functional
residues highlighted.
F. Summary Table
TABLE 7. Summary of features shared by GGT1 and potential D. melanogaster ortholog
CG6461.
Length
(AA)
Gammaglutamyltranspeptidase 1
(GGT1, NP_001275762.1,
PDB: 4GDX)

569

Gammaglutamyltranspeptidase
(CG6461, NP_573303.1)

579

Domain
Architecture
(Pfam, range)
Gammaglutamyltranspeptidase
(PF01019)
55-564
Gammaglutamyltranspeptidase
(PF01019)
56-566

Functional Residues
(aligned matches in
D. melanogaster)

Sequence
ID%

Structural
Overlap
(RMSD)

39% ID
54% SIM

1.126 Å

T381

T382

DPEP1
The sixth gene in this set, CG6154 (“DPEP,” NP_733146.2), encodes a 434 amino acid
metallopeptidase that shares 42% identity and 56% similarity with human DPEP1 (“Dipeptidase,
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renal,” NP_004404.1). Both enzymes contain a single Membrane dipeptidase (PF01244) domain
spanning the majority of the protein. DPEP1 is known to regulate leukotriene activity by
catalyzing the conversion of leukotriene D4 (LTD4) to leukotriene E4 (LTE4) using zinc as a
cofactor. To that end, the residues H36, D38, E141, H214 and H235 are reported to be essential
for coordinating the zinc ions required for catalysis. Aligned against CG6154, these residues
correspond to H71, D73, E184, H257 and H278. This high degree of similarity extends to the
tertiary structure, as the superimposed structure of human DPEP1 (1ITQ) and the predicted
structure of CG6154 display a RMSD of 0.523 Å.
A. Predicted Secondary Structure
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FIG. 43. Predicted secondary structure of DPEP1 and CG6154 calculated using
PROMALS3D.
B. Domain Architecture

FIG. 44. Predicted domain architecture of DPEP1 and CG6154 determined using Interpro
and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG6154. All three tools identify chain A of 1ITQ (human renal dipeptidase) as a high-scoring
match suitable for single-template modeling.
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CG6154 Range
53-425

Template Range
2-361

% Identity
50%

% Similarity
72%

E-Value
1.5e-113

FIG. 45. HMM profile of CG6154 aligned against chain A of 1ITQ, a template structure
selected for modeling CG6154.
2. Validation
The quality of the CG6154 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -7.99). The ProSA per-residue energy score graph is also favorable, showing a score that is
consistently negative over a window size of 40 residues.
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Position
FIG. 46. Validation of the CG6154 model: ProQ2 quality score mapped to a 3D model of
CG6154 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
D. Structural Analyses
A structural superposition reveals that the CG6154 model and human renal dipeptidase
(1ITQ) display a similar secondary structure architecture across the modeled region with
substantial full-length overlap. The pairwise alignment generated by this structural superposition
also indicates substantial conservation of residues having similar physiochemical properties.
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1. Secondary Structure

FIG. 47. Pairwise alignment of CG6154 and 1ITQ generated from structural superposition
with shared secondary structure elements and conserved residues highlighted.
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2. Physiochemical Properties

FIG. 48. Pairwise alignment of CG6154 and 1ITQ generated from structural superposition
with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

DPEP1 (PDB: 1ITQ) and CG6154 Model
D. melanogaster
DPEP1 Structure
Superimposed
Model

FIG. 49. DPEP1 (1ITQ, cyan-blue) superimposed on the predicted structure of CG6154
(green-red). RMSD: 0.523 Å.
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DPEP1 (PDB: 1ITQ) and CG6154 Model Superimposed

FIG. 50. DPEP1 (1ITQ, cyan-blue) superimposed on the predicted
structure of CG6154 (green-red), with potential matches for conserved
functional residues highlighted.
F. Summary Table
TABLE 8. Summary of features shared by DPEP1 and potential D. melanogaster ortholog
CG6154.
Length
(AA)
Dipeptidase, renal (DPEP1,
NP_004404.1, PDB: 1ITQ)
DPEP
(CG6154, NP_733146.2)

411
434

Domain
Architecture
(Pfam, range)
Membrane dipeptidase
(PF01244)
31-349
Membrane dipeptidase
(PF01244)
66-393

Functional Residues
(aligned matches in
D. melanogaster)
H36, D38, E141,
H214 and H235
H71, D73, E184,
H257 and H278

Sequence
ID%

Structural
Overlap
(RMSD)

42% ID
56% SIM

0.523 Å

GPX1
The seventh gene in this set, CG12013 (“glutathione peroxidase,” NP_728870.1),
encodes a 169 amino acid selenoprotein that is 32% identical and 44% similar to human GPX1
(“glutathione peroxidase 1,” NP_000572.2). As part of the eicosanoid pathway, GPX-1 converts
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the 12(S)-HPETE produced by lipoxygenase-12 (12-LOX) into 12(S)-HETE. GPX1 requires a
selenocysteine residue (U49) for catalysis. CG12013’s amino acid sequence indicates that a
cysteine residue is present at the corresponding position in this enzyme. However, this residue
may in fact be a selenocysteine, as this substitution is unlikely to be detected by standard
sequencing techniques. A structural alignment of human GPX1 (2F8A) and the predicted
structure of CG12013 reveals an RMSD of 0.699 Å.
A. Predicted Secondary Structure

FIG. 51. Predicted secondary structure of GPX1 and CG12013 calculated using
PROMALS3D.
B. Domain Architecture

FIG. 52. Predicted domain architecture of GPX1 and CG12013 determined using Interpro
and Pfam.
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C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG12013. All three tools identify chain A of 2F8A (human glutathione peroxidase 1) as a highscoring match suitable for single-template modeling.
CG12013 Range
7-122

Template Range
20-140

% Identity
39%

% Similarity
62%

131-169

168-206

49%

64%

E-Value
2.3e-17

9.7e-05

FIG. 53. HMM profile of CG12013 aligned against chain A of 2F8A, a template structure
selected for modeling CG12013.
2. Validation
The quality of the CG12013 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -7). The ProSA per-residue energy score graph is also favorable, showing a score that is
consistently negative over a window size of 40 residues.
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Position
FIG. 54. Validation of the CG12013 model: ProQ2 quality score mapped to a 3D model of
CG12013 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
D. Structural Analyses
A structural superposition reveals that the CG12013 model and human glutathione
peroxidase 1 (2F8A) display a similar secondary structure architecture across the modeled region
with substantial full-length overlap. The pairwise alignment generated by this structural
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superposition also indicates substantial conservation of residues having similar physiochemical
properties.
1. Secondary Structure

FIG. 55. Pairwise alignment of CG12013 and 2F8A generated from structural
superposition with shared secondary structure elements and conserved residues
highlighted.
2. Physiochemical Properties

FIG. 56. Pairwise alignment of CG12013 and 2F8A generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
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E. Analysis of Functional Residues

GPX1 (PDB: 2F8A) and CG12013 Model
D. melanogaster
GPX1 Structure
Superimposed
Model

FIG 57. GPX1 (2F8A, cyan-blue) superimposed on the predicted structure of CG12013
(green-red). RMSD: 0.699 Å.

GPX1 (PDB: 2F8A) and X Model Superimposed

FIG. 58. GPX1 (2F8A, cyan-blue) superimposed on the predicted
structure of CG12013 (green-red), with potential matches for conserved
functional residues highlighted.
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F. Summary Table
TABLE 9. Summary of features shared by GPX1 and potential D. melanogaster ortholog
CG12013.

Glutathione peroxidase 1
(GPX1, NP_000572.2,
PDB: 2F8A)
Glutathione peroxidase
(CG12013, NP_728870.1)

Length
(AA)

Domain
Architecture
(Pfam, range)

Functional Residues
(aligned matches in
D. melanogaster)

203

GSHPx (PF00255)
16-130

C49

169

GSHPx (PF00255)
13-122

C45

Sequence
ID%

Structural
Overlap
(RMSD)

32% ID
44% SIM

0.699Å

CPA1
The eighth and final gene in this set, CG18585 (“CPA,” NP_609132.1) encodes a 422
amino acid protein that is 34% identical and 54% similar to human CPA1 (“Carboxypeptidase
A1,” NP_001859.1). CPA1 is a metallocarboxypeptidase that requires a zinc atom as a cofactor
for catalysis. CPA1 has been shown to convert the potent leukotriene C4 (LTC4) to the less
potent leukotriene F4 (LTF4) by hydrolysis of an amide bond, suggesting that CPA1 serves to
reduce inflammation. The residues H179, E182, H306 and E380 are reportedly required for
catalysis. These residues correspond to H178, E181, H305 and E382 in CPA. Aligned, the
structure of human CPA1 (3FJU) and the predicted structure of CG18585 display an RMSD of
0.753 Å.
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A. Secondary Structure Prediction

FIG. 59. Predicted secondary structure of CPA1 and CG18585 calculated using
PROMALS3D.
B. Domain Architecture
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FIG. 60. Predicted domain architecture of CPA1 and CG18585 determined using Interpro
and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG18585. All three tools identify chain A of 2V77 (human carboxypeptidase A1) as a highscoring match suitable for single-template modeling. Human carboxypeptidase A1 undergoes
posttranslational processing, which results in cleavage of the N-terminal portion of the
polypeptide spanning from position 1 to 110 (i.e., including a signal peptide spanning 1-16 and
an activation peptide spanning 17-110). The mature form of the enzyme consists of the Cterminal portion of the polypeptide (i.e., position 111-419). CG18585 is predicted to share a
similar architecture, as the N-terminal regions aligns against the sequence of the human
carboxypeptidase A1 activation peptide. The C-terminal region of CG18585 which appears to
correspond to the sequence encoding mature human carboxypeptidase A1 was modeled for this
study.
CG18585 Range
114-417

Template Range
4-305

% Identity
40%

66

% Similarity
65%

E-Value
3.8e-69

FIG. 61. HMM profile of CG18585 aligned against chain A of 2V77, a template structure
selected for modeling CG18585.
2. Validation
The quality of the CG18585 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -7.75). The ProSA per-residue energy score graph is also favorable, showing a score that is
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consistently negative over a window size of 40 residues.

Position
FIG. 62. Validation of the CG18585 model: ProQ2 quality score mapped to a 3D model of
CG18585 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
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D. Structural Analyses
1. Secondary Structure
A structural superposition reveals that the CG18585 model and human carboxypeptidase
A1 (2V77) display a similar secondary structure architecture across the modeled region with
substantial full-length overlap. The pairwise alignment generated by this structural superposition
also indicates substantial conservation of residues having similar physiochemical properties.
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FIG. 63. Pairwise alignment of CG18585 and 2V77 generated from structural
superposition with shared secondary structure elements and conserved residues
highlighted.
2. Physiochemical Properties

FIG. 64. Pairwise alignment of CG18585 and 2V77 generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

CPA1 (PDB: 2V77) and CG18585 Model
D. melanogaster
CPA1 Structure
Superimposed
Model

FIG. 65. Truncated CPA1 (2V77, cyan-blue) superimposed on the predicted structure of
CG18585 (green-red). RMSD: 0.753 Å.
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Truncated CPA1 (PDB: 2V77) and CG18585 Model Superimposed

FIG. 66. Truncated CPA1 (2V77, cyan-blue) superimposed on the predicted
structure of CG18585 (green-red), with potential matches for conserved
functional residues highlighted.
F. Summary Table
TABLE 10. Summary of features shared by CPA1 and potential D. melanogaster ortholog
CG18585.
Length
(AA)

Carboxypeptidase A1
(CPA1, NP_001859.1,
PDB: 3FJU)

CPA (CG18585,
NP_609132.1)

419

422

Domain
Architecture
(Pfam, range)
Carboxypeptidase activation
peptide (PF02244)
26-100
Zinc carboxypeptidase
(PF00246)
128-406
Carboxypeptidase activation
peptide (PF02244)
33-106
Zinc carboxypeptidase
(PF00246)
128-408
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Functional Residues
(aligned matches in
D. melanogaster)

Sequence
ID%

Structural
Overlap
(RMSD)

34% ID
54% SIM

0.753 Å

H179, E182, H306
and E380

H178, E181, H305
and E382

Group 2: The Midrange Candidates
Five candidates were identified in the search based more on structural similarity than
underlying sequence conservation. Members of this set share 20-30% sequence identity with the
human target, but share similarity at the fold level and possess at least one conserved functional
residue.
HPGDS
The first gene in this set, CG8938 (GST-S1, NP_725653.1) encodes a 249 amino acid
glutathione-S-transferase enzyme, which displays 27% identity and 43% similarity to human
HPGDS, (“Hematopoietic Prostaglandin D synthase,” NP_055300.1). HPGDS, alternatively
known as Prostaglandin-H2 D-isomerase, is a glutathione-requiring prostaglandin D synthase.
HPGDS operates as a homodimer, which can optionally be activated by Ca2+ and Mg2+ to
increase catalytic efficiency to 150% of the basal level [86]. Coordination of the metallic ion
ligands is coordinated by D93, D96 and D97. CG8938 and GST-S1 share an identical domain
architecture, with an N-terminal GST-N domain (PF02798) and a C-terminal GST-C domain
(PF00043). Similarly, CG8938 possesses aligned matches for two of the three aspartic residues
requires for enhanced catalytic activity, at positions D139 and D143 (corresponding to D93 and
D97 in HPGDS). At the corresponding position aligned to D96, CG8938 instead has an
asparagine (N142). However, mutagenesis studies by Inouie et al. have shown that a D to N
substitution at this same position in HPGDS actually increases PGD2 synthesis [95]. In addition
to this sequence-based evidence, superposition of the predicted CG8938 structure and human
HPGDS (1IYI) reveals an RMSD of 1.045 Å.
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A. Secondary Structure Prediction

FIG. 67. Predicted secondary structure of HPGDS and CG8938 calculated using
PROMALS3D.
B. Domain Architecture

FIG. 68. Predicted domain architecture of HPGDS and CG8938 determined using Interpro
and Pfam.
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C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling CG8938.
All three tools identify chain A of 1IYH (human hematopoietic prostaglandin D synthase) as a
high-scoring match suitable for single-template modeling.
CG8938 Range
49-248

Template Range
2-197

% Identity
36%

% Similarity
61%

E-Value
7.9e-36

FIG. 69. HMM profile of CG8938 aligned against chain A of 1IYH, a template structure
selected for modeling CG8938.
2. Validation
The quality of the CG8939 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -6.16). The ProSA per-residue energy score graph is also favorable, showing a score that is
consistently negative over a window size of 40 residues, after the initial N-terminal segment that
was generated using ab initio methods. This proline rich N-terminal segment may include a
signal peptide or other processing-related motif.
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Position
FIG. 70. Validation of the CG8938 model: ProQ2 quality score mapped to a 3D model of
CG8938 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
D. Structural Analyses
A structural superposition reveals that the CG8938 model and human hematopoietic
prostaglandin D synthase (1IYH) display a similar secondary structure architecture across the
modeled region with substantial full-length overlap. The pairwise alignment generated by this
structural superposition also indicates substantial conservation of residues having similar
physiochemical properties.
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1. Secondary Structure

FIG. 71. Pairwise alignment of CG8938 and 1IYH generated from structural superposition
with shared secondary structure elements and conserved residues highlighted.
2. Physiochemical Properties

FIG. 72. Pairwise alignment of CG8938 and 1IYH generated from structural superposition
with conserved residues highlighted using the CLUSTALX color scheme.
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E. Analysis of Functional Residues
TABLE 11. Summary of features shared by HPGDS and potential D. melanogaster
ortholog CG8938.

HPGDS (PDB: 1IYI) and CG8938 Model
D. melanogaster
HPGDS Structure
Superimposed
Model

FIG. 73. HPGDS (1IYI, cyan-blue) superimposed on the predicted structure of CG8938
(green-red). RMSD: 1.045 Å.

HPGDS (PDB: 1IYI) and CG8938 Model Superimposed

FIG. 74. HPGDS (1IYH, cyan-blue) superimposed on the predicted
structure of CG8938 (green-red), with potential matches for conserved
functional residues highlighted.
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F. Summary Table

Hematopoietic
Prostaglandin D
synthase
(HPGDS, NP_055300.1,
PDB: 1IYI)
Glutathione S
transferase S1 (CG8938,
NP_725653.1)

Length
(AA)

Domain
Architecture
(Pfam, range)

Functional Residues
(aligned matches in
D. melanogaster)

160

GST-N domain (PF02798)
4-73
GST-C domain (PF00043)
81-185

D93, D96, D97

184

GST-N domain (PF02798)
50-119
GST-C domain (PF00043)
141-235

Sequence
ID%

27% ID
43% SIM

Structural
Overlap
(RMSD)

1.045 Å

D139, D143, N142

PTGES3
The second gene in this set, CG16817 (NP_649925.1) encodes a 184 amino acid protein,
which displays 24% identity and 40% similarity to human PTGES3 (“prostaglandin E synthase
3,” NP_006592.3). In contrast to PTGES1 and PTGES2 discussed above, PTGES3 is a cytosolic
protein. However, all three enzymes share the same catalytic function, i.e., oxidoreduction of
prostaglandin endoperoxide H2 (PGH2) to prostaglandin E2 (PGE2). PTGES3 and CG16817 share
an identical domain architecture, with a CS Domain (PF04969) spanning the N-terminus to the
middle of the protein. The C-terminal region of PTGES3 is notable for showing a compositional
bias towards aspartic acid and glutamic acid residues in the range spanning 108 to 160. At this
time, only one crystal structure for PTGES3 has been published (1EJF) and this structure is
limited to a truncated version of the protein spanning residue 1 to 110, i.e., the acidic C-terminal
region has not been crystalized. An alignment of PTGES3 and CG16817 shows that CG16817
also displays a compositional bias towards acidic residues at its C-terminus, though it is unclear
what role this serves in either protein. We were unable to generate a full-length model of
CG16817 due to a lack of any suitable template structure for the C-terminal acidic region.
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However, the truncated CG16817 model (residues 1 to 113) shows a RMSD of 0.823 Å
compared to PTGES3.
A. Secondary Structure Prediction

FIG. 75. Predicted secondary structure of PTGES3 and CG16817 calculated using
PROMALS3D.
B. Domain Architecture

FIG. 76. Predicted domain architecture of PTGES3 and CG16817 determined using
Interpro and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG16817. All three tools identify chain A of 1EJF (human prostaglandin E synthase 3) as a
high-scoring match suitable for single-template modeling of the first two-thirds of CG16817
(i.e., the region spanning1-110), which includes the CS domain mapped to the segment spanning
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10-85. The crystal structure of the acidic (E/D-rich) C-terminus of human prostaglandin E
synthase 3 was not included in 1EJF and is currently unknown. Sequence analysis of CG16817
reveals that a similar E/D-rich segment at the C-terminus of the polypeptide, providing further
support for CG16817 being orthologous to or at least functionally similar to human
prostaglandin E synthase 3. The modeled portion of CG17817 is predicted to be structured as a
β-sandwich consisting of two sheets of anti-parallel β-strands, which matches the structure of the
corresponding portion of human prostaglandin E synthase 3. Attempts to model the acidic Cterminal segment using ab initio methods were unable to generate a high-confidence structure. It
should be noted that this segment is predicted to be an intrinsically disordered region (e.g., as
predicted by the IUPRed server, http://iupred.enzim.hu/). As a result, the present structural
analysis of CG16817 is limited to the segment spanning 1-110 of the full-length polypeptide
sequence.
CG16817 Range
9-127

Template Range
3-121

% Identity
26%

% Similarity
46%

E-Value
8.7e-10

FIG. 77. HMM profile of CG16817 aligned against chain A of 1EJF, a template structure
selected for modeling CG16817.
2. Validation
The quality of the CG16817 model was evaluated using ProQ2, and ProSA as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -2.96). The ProSA per-residue energy score graph is also favorable, showing a score that is
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consistently negative over a window size of 40 residues, except for the loop regions connecting
the β-sandwich halves. As noted above, this model is truncated and excludes the acidic Cterminus of CG16817, which may contribute to the tertiary structure of the full-length protein in
a manner that is not accurately represented by the current model. However, the modeled structure
has a reasonable quality score and appears to be structurally analogous to the crystalized portion
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of human prostaglandin E synthase 3, which is similarly truncated.

Position
FIG. 78. Validation of the CG16817 model: ProQ2 quality score mapped to a 3D model of
CG16817 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
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D. Structural Analyses
A structural superposition reveals that the CG16817 model and human prostaglandin E
synthase 3 (1EJF) display a similar secondary structure architecture across the modeled region
with substantial full-length overlap. The pairwise alignment generated by this structural
superposition also indicates substantial conservation of residues having similar physiochemical
properties.
1. Secondary Structure

FIG. 79. Pairwise alignment of CG16817 and 1EJF generated from structural
superposition with shared secondary structure elements and conserved residues
highlighted.
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2. Physiochemical Properties

FIG. 80. Pairwise alignment of CG16817 and 1EJF generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

PTGES3 (PDB: 1EJF) and CG16817 Model (Partial)
Truncated
D. melanogaster
Superimposed
PTGES3 Structure Model (Partial)

FIG. 81. Truncated PTGES3 (1EJF, cyan-blue) superimposed on
the predicted structure of CG16817 (green-red). RMSD: 0.823 Å.

PTGES3 (PDB: 1EJF) and CG16817 Model (Partial) Superimposed

FIG. 82. Truncated PTGES3 (1EJF, cyan-blue) superimposed on the predicted
structure of CG16817 (green-red), with potential matches for conserved
functional residues highlighted.
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F. Summary Table
TABLE 12. Summary of features shared by PTGES3 and potential D. melanogaster
ortholog CG16817.

Prostaglandin E synthase 3
(PTGES3, NP_006592.3,
PDB: 1EJF)

Uncharacterized protein
(CG16817, NP_649925.1)

Length
(AA)

Domain
Architecture
(Pfam, range)

Functional Residues
(aligned matches in
D. melanogaster)

160

CS Domain (PF04969)
4-79

N/A

184

CS Domain (PF04969)
10-85

Sequence
ID%

Structural
Overlap
(RMSD)

24% ID
40% SIM

0.823 Å

N/A

CBR1
The third gene in this set, CG11200 (“CBR,” NP_611471.1) encodes a 355 amino acid
protein that displays 20% identity and 33% similarity to human CBR1 (“carbonyl reductase 1,”
NP_001748.1). CBR1 is a NADPH-dependent reductase with broad substrate specificity, e.g., it
can convert PGE2 to PGF2α. It has been reported that CBR1 binds to NADP via N90 and that
Y194 serves as a proton acceptor for the reaction. A corresponding match for both of these
residues can be found in CG11200 at positions N154 and Y233. An alignment of human CBR1
(3BHJ) against the predicted model for CG11200 shows an RMSD of 1.153 Å.
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A. Secondary Structure Prediction

FIG. 83. Predicted secondary structure of CBR1 and CG11200 calculated using
PROMALS3D.
B. Domain Architecture

FIG. 84. Predicted domain architecture of CBR1 and CG11200 determined using Interpro
and Pfam.
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C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG11200. All three tools identify chain A of 3BHJ (human carbonyl reductase 1 complexed with
glutathione) as a high-scoring match suitable for single-template modeling.
CG11200 Range
68-206

Template Range
5-143

% Identity
34%

% Similarity
56%

224-317

184-269

34%

59%

E-Value
1.6e-12

1.6e-12

FIG. 85. HMM profile of CG11200 aligned against chain A of 3BHJ, a template structure
selected for modeling CG11200.
2. Validation
The quality of the CG11200 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -6.55). The ProSA per-residue energy score graph is also favorable, showing a score that is
consistently negative over a window size of 40 residues, except for the N-terminus (which is
predicted to be a signal peptide) and a single loop region.
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Position
FIG. 86. Validation of the CG11200 model: ProQ2 quality score mapped to a 3D model of
CG11200 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
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D. Structural Analyses
1. Secondary Structure

FIG. 87. Pairwise alignment of CG11200 and 3BHJ generated from structural
superposition with secondary structure elements and conserved residues highlighted.
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2. Physiochemical Properties

FIG. 88. Pairwise alignment of CG11200 and 3BHJ generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

CBR1 (PDB: 3BHJ) and CG11200 Model
D. melanogaster
CBR1 Structure
Superimposed
Model

FIG 89. CBR1 (3BHJ, cyan-blue) superimposed on the predicted structure of CG11200
(green-red). RMSD: 1.153 Å.
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CBR1 (PDB: 3BHJ) and CG11200 Model Superimposed

FIG. 90. CBR1 (3BHJ, cyan-blue) superimposed on the predicted
structure of CG11200 (green-red), with potential matches for conserved
functional residues highlighted.
F. Summary Table
TABLE 13. Summary of features shared by CBR1 and potential D. melanogaster ortholog
CG11200.

Carbonyl reductase 1
(CBR1, NP_001748.1,
PDB: 3BHJ)

CBR (CG11200,
NP_611471.1)

Length
(AA)

Domain
Architecture
(Pfam, range)

Functional Residues
(aligned matches in
D. melanogaster)

277

Short chain dehydrogenase
domain (PF16152)
6-151

N90 and Y194

355

Short chain dehydrogenase
domain (PF16152)
68-252

89

N154 and Y233

Sequence
ID%

Structural
Overlap
(RMSD)

20% ID
33% SIM

1.153 Å

HPGD
The fourth gene in this set, CG18814 (NP_652673.2), encodes a 267 amino acid protein
that displays 26% identity and 47% similarity to human HPGD (“15-hydroxyprostaglandin
dehydrogenase NAD(+),” NP_000851.2). HPGD catalyzes the conversion of the 15-hydroxyl
group of prostaglandins into a keto group, which strongly reduces the biologic activity of these
molecules. As a result, HPGD is considered the primary enzyme responsible for degradation of
prostaglandins. It has been reported that N91, S138, Q148 and Y151 are required for catalysis.
[96]. CG18814 residues N89, S137 and Y150 of CG18814 align with these catalytic residues and
are oriented at overlapping or directly adjacent positions in close proximity in the structural
alignment of the CG18814 model against the structure of HPGD. CG18814 lacks an obvious
analog for Q148, which is located in a flexible loop region. However, CG18814 possesses a
structurally-aligned loop region which contains Q142. Q148 and Q142 are located within
approximately 5Å of each other and oriented similarly in a static superposition of the predicted
model and crystal structure and may be functionally analogous. Moreover, both proteins have an
identical domain architecture, with a Short-chain dehydrogenase domain (PF00106) spanning
from the N-terminus to approximately residue 180. Superposition of human HPGD (2GDZ) and
the predicted structure of CG18814 reveals an RMSD of 0.715 Å.
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A. Secondary Structure Prediction

FIG. 91. Predicted secondary structure of HPGD and CG18814 calculated using
PROMALS3D.
B. Domain Architecture

FIG. 92. Predicted domain architecture of HPGD and CG18814 determined using Interpro
and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG18814. All three tools identify chain A of 2GDZ (human 15-hydroxyprostaglandin
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dehydrogenase 1 complexed with NAD+) as a high-scoring match suitable for single-template
modeling.
CG18814 Range
4-242

Template Range
6-249

% Identity
31%

% Similarity
59%

E-Value
1.3e-34

FIG. 93. HMM profile of CG18814 aligned against chain A of 2GDZ, a template structure
selected for modeling CG18814.
2. Validation
The quality of the CG18814 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -6.94). The ProSA per-residue energy score graph is also favorable, showing a score that is
consistently negative over a window size of 40 residues, except for the putative active site and a
C-terminal loop.
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Position
FIG. 94. Validation of the CG18814 model: ProQ2 quality score mapped to a 3D model of
CG18814 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
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D. Structural Analyses
1. Secondary Structure

FIG. 95. Pairwise alignment of CG18814 and 2GDZ generated from structural
superposition with CG18814 with shared secondary structure elements and conserved
residues highlighted.
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2. Physiochemical Properties

FIG. 96. Pairwise alignment of CG18814 and 2GDZ generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

HPGD (PDB: 2GDZ) and CG18814 Model
D. melanogaster
HPGD Structure
Superimposed
Model

FIG. 97. HPGD (2GDZ, cyan-blue) superimposed on the predicted
structure of CG18814 (green-red). RMSD: 0.715 Å.

HPGD (PDB: 2GDZ) and CG18814 Model Superimposed

FIG. 98. HPGD (2GDZ, cyan-blue) superimposed on the predicted
structure of CG18814 (green-red), with potential matches for conserved
functional residues highlighted.
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F. Summary Table
TABLE 14. Summary of features shared by HPGD and potential D. melanogaster ortholog
CG18814.

15-hydroxyprostaglandin
dehydrogenase NAD(+)
(HPGD, NP_000851.2,
PDB: 2GDZ)

Uncharacterized protein
(CG18814, NP_652673.2)

Length
(AA)

Domain
Architecture
(Pfam, range)

Functional Residues
(aligned matches in
D. melanogaster)

266

Short chain
dehydrogenase domain
(PF00106)
6-170

Y151

267

Short chain
dehydrogenase domain
(PF00106)
7-166

Sequence
ID%

Structural
Overlap
(RMSD)

26% ID
47% SIM

0.715 Å

Y150

TBXAS1
The fifth and final gene in this set, CG3616 (“CYP450-9c1,” NP_523850.1) encodes a
cytochrome p450 oxidase, which displays 27% identity and 45% similarity to TBXAS1
(“thromboxane A synthase,” NP_001052.2). TBXAS1 localizes to the endoplasmic reticulum
membrane, where it catalyzes the conversion of PGH2 to thromboxane A2 (TBA2). TBXAS1 is
categorized as a cytochrome p450 family (CYP450) enzyme based on sequence similarity. This
categorization is illustrated by the fact that the only pfam domain identified in TBXAS1 has a
Cytochrome P450 domain (PF00067) spanning the majority of the protein. CYP450 enzymes are
highly conserved in eukaryotes, where they catalyze many reactions involved in drug
metabolism and synthesis of cholesterol, steroids and other lipids. However, this ubiquitous
nature of CYP450 enzymes makes it difficult to identify potential orthologs for any one specific
enzyme within the family. CG3616 was selected as a candidate from the set of eight candidates
with similar sequences after taking into account the initial sequence comparison, the
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transmembrane helix pattern (calculated using TOPCONS) and the alignment score against a
multiple sequence alignment of known or high confidence TBXAS1 orthologs
A. Secondary Structure Prediction

FIG. 99. Predicted secondary structure of TBXAS1 and CG3616 calculated using
PROMALS3D.
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B. Domain Architecture

FIG. 100. Predicted domain architecture of TBXAS1 and CG3616 determined using
Interpro and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG3616. All three tools identify chain A of 4DGZ (human CYP450 3A4) as a high-scoring
match suitable for single-template modeling.
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CG3616 Range
17-519

Template Range
2-476

% Identity
33%

% Similarity
62%

E-Value
2.8e-70

FIG. 101. HMM profile of CG3616 aligned against chain A of 4DGZ, a template structure
selected for modeling CG3616.
2. Validation
The quality of the CG3616 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -8). The ProSA per-residue energy score graph is also favorable, showing a score that is
consistently negative over a window size of 40 residues, except for the N-terminus which is
predicted to be a signal peptide and a single loop region.
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FIG. 102. Validation of the CG3616 model: ProQ2 quality score mapped to a 3D model of
CG3616 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
D. Structural Analyses
A crystal structure is currently unavailable for human thromboxane A synthase.
However, based on sequence analysis this enzyme is predicted to display the typical CYP450
fold and high quality models (based on CYP450 crystal strctures) are available. For example, a
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high confidence model of human thromboxane A synthase is available from the SWISS MODEL
database and was used in this study as a stand-in for the likely actual structure of human
thromboxane A synthase.
A structural superposition reveals that the CG3616 model and the predicted human
thromboxane A synthase model display a similar secondary structure architecture across the
modeled region with substantial full-length overlap. The most notable difference occurs at
segment 282-304 of CG3616, which consists of a single short α-helix bordered by loops on
either side (α-helix 14). The corresponding segment of the TBXAS1 model (286-325) consists of
two α-helices joined by a short loop. The pairwise alignment generated by this structural
superposition also indicates substantial conservation of residues having similar physiochemical
properties.
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1. Sequence Analysis

FIG. 103. Pairwise alignment of CG3616 and 4DGZ generated from structural
superposition with shared secondary structure elements and conserved residues
highlighted.
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2. Physiochemical Properties

FIG. 104. Pairwise alignment of CG3616 and 4DGZ generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

TBXAS1 (SWISS-MODEL) and CG3616 Model
D. melanogaster
TBXAS1 Model
Superimposed
Model

FIG. 105. TBXAS1 (SWISS-MODEL, cyan) superimposed on the predicted
structure of CG3616 (green). RMSD: 0.699 Å.
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TBXAS1 (SWISS-MODEL) and CG3616 Model Superimposed

FIG. 106. TBXAS1 (4DGZ, cyan-blue) superimposed on the predicted
structure of CG3616 (green-red), with potential matches for conserved
functional residues highlighted.
F. Summary Table
TABLE 15. Summary of features shared by TBXAS1 and potential D. melanogaster
ortholog CG3616.

Thromboxane A synthase
(TBXAS1, NP_001052.2,
PDB: N/A (modeled))
Cytochrome P450-9c1
(CG3616, NP_610820.1)

Length
(AA)

Domain
Architecture
(Pfam, range)

Functional Residues
(aligned matches in
D. melanogaster)

534

Cytochrome P450
domain (PF00067)
44-530

C479

518

Cytochrome P450
domain (PF00067)
34-513

104

C462

Sequence
ID%

Structural
Overlap
(RMSD)

27% ID
45% SIM

0.699 Å

Group 3: The Most Distant Candidates
Many of the putative orthologs identified in D. melanogaster although divergent in
sequence from the human target, are similar enough that traditional methods for analyzing and
aligning sequences can be utilized. However, for a small subset, the sequences are so divergent
(i.e., 20-20% identical) that a more intensive analysis was required to determine whether further
study was justified.
PTGS1/PTGS2
The search for a cyclooxygenase ortholog proved to be one of these difficult cases. As
noted above, it is widely accepted that D. melanogaster lacks a cyclooxygenase ortholog.
However, there have been sporadic reports of prostaglandin detected in D. melanogaster extracts
over the years. The human genome encodes three major cyclooxygenase isozymes via two loci.
PTGS1 encodes Cox-1 (a constitutive cyclooxygenase), whereas PTGS2 encodes Cox-2 (which
is inducible and expressed in a tissue-specific manner) A truncated and poorly characterized
isoform of PTGS1, Cox-3 is also known to be expressed in certain cells, and reportedly
demonstrates reduced prostaglandin synthesis activity relative to COX-1 [97]. Cox-1 and Cox-2
operate as homodimers and are characterized by two domains: an N-terminal EGF-like domain
(IPR000742) and an animal heme peroxidase domain (PF03098). The former allows for
association with the cell and nuclear membrane while the latter is responsible for the
cyclooxygenase activity. The Cox enzymes initiate the prostaglandin synthesis pathway by
converting arachidonic acid, or other polyunsaturated fatty acid (PUFA) substrates, into the
unstable intermediate PGG2 followed by PGH2. During this process, it has been reported that a
small amount of the PUFA substrate is converted into a racemic mixture of 15Hydroxyicosatetraenoic acids (i.e., 15-HETEs), which may be processed into lipoxins, a poorly
understood class of anti-inflammatory eicosanoids. The Cox-1 and Cox-2 enzymes contains two
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active sites: a heme with peroxidase activity, responsible for the reduction of PGG2 to PGH2, and
a cyclooxygenase site, where arachidonic acid is converted into the hydroperoxy endoperoxide
prostaglandin G2 (PGG2). Extensive studies have been performed on the sheep ortholog of Cox1, (NP_001009476.1; PDB: 1CQE), which is a proxy for the human ortholog [98]. These studies
reveal that cyclooxygenase activity is mediated by Y385, which forms a radical capable of
abstracting a hydrogen from the PUFA substrate (e.g., carbon-13 of arachidonic acid). H207 and
H388 are also required for the dual peroxidase and cyclooxygenase functions performed by these
enzymes [99, 100]. Other functional residues identified in the literature include R120, Q203,
V349, and S530 [101]. R120 interacts with C-1 of the PUFA substrate, arachidonic acid [102].
Q203 is conserved among mammalian Cox enzymes, though the function of this residue is
currently unknown. V349 is believed to play a role in substrate specificity; mammalian Cox
enzymes share this residue and show a substrate preference for arachidonic acid, while
invertebrate Cox enzymes that have a leucine at this position display specificity for linoleic acid
[103]. and S530 acetylation is the basis for Cox-2 inhibition by aspirin [104].
An initial screen of D. melanogaster using BLASTP failed to identify meaningful hits.
However, iterative HMMER searches were able to identify four potential candidates: CG4009
(NP_650588.2), CG6969 (“Cardinal,” NP_651081.1), CG7660 (“Pxt,” NP_650648.3) and
CG3477 (“Pxd,” NP_996223.1). Each of these candidates was added to a previously generated
multiple sequence alignment containing PTGS1 and known or high confidence predicted
orthologs using MAFFT. The presence of absence of functional residues at or near aligned
positions was noted. Similarly, the candidates were analyzed to determine the secondary
structure and domain architecture of each protein. Following this filtering step, only two proteins
remained as viable candidates for further study: CG4009 and CG6969. Both appear to have the
requisite catalytic triad and share a similar domain architecture, though they each lack the N106

terminal EGF-like domain. Notably, putative analogs for the H207, Y385 and H388 catalytic
triad appear to be present on CG4009 at H163, Y399, H401 and on CG7660 at H222, Y564,
H568, respectively.
Structural models of CG4009 and CG6969, and CG7660 were built and validated as
described above. PTGS1 (3N8V) and the predicted structure for CG4009 both display a
cyclooxygenase fold, and the predicted catalytic domains are superimposable with a RMSD of
1.875 Å. CG7660 and CG6969 each display a similar tertiary structure and with predicted
catalytic domains that overlap with PTGS1 with a RMSD of 2.810 and 2.942 Å, respectively.
The predicted structures differ from PTGS1at their N-terminus, which is expected given the
absence of the EGF-like domain, though the CG4009 structure is marginally closer. In any event,
these three structures present the necessary catalytic residues in a similar orientation as in PTGS1
and so likely possess cyclooxygenase activity.

107

A. Secondary Structure Prediction

FIG. 107. Predicted secondary structure of PTGS1 and CG4009 calculated using
PROMALS3D.
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B. Domain Architecture

FIG. 108. Predicted domain architecture of PTGS1 and CG4009 determined using Interpro
and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG4009. All three tools identified human COX-1 and COX-2, as well as the mouse and sheep
orthologs, as potential templates for modeling a substantial portion of the animal haem
peroxidase domain which spans 95-617 of CG4009 (e.g., 5F1A, 1IGZ). Lactoperoxidases, alphadioxygenase and myeloperoxidase structures are also identified as templates for this portion of
CG4009. However, none of these templates aligns well enough with CG4009 to support high
confidence single-template modeling. As a result, I-TASSER was used to generate a multitemplate model of CG4009 based on six templates: 4HHR, 3FAQ, 3Q9K, 1CXP, 2GJ1, and
1CVU.
TABLE 16. Templates selected for compositing modeling of CG4009 using
I-TASSER.
Template

Organism

4HHR

A.thaliana

3FAQ
3Q9K
1CXP
2GJ1
1CVU

B. bubalis
B. taurus
Human
B. taurus
M. musculus

Protein
Fatty acid
dioxygenase
Lactoperoxidase
Lactoperoxidase
Myeloperoxidase
Lactoperoxidase
COX-2
109

% Identity Coverage
20%

90%

30%
28%
29%
28%
18%

85%
85%
83%
84%
76%

The multi-template alignment used by I-TASSER to generate a full-length model of
CG4009 is shown below as Fig. 109. The full-length model is predicted to have a TM-SCORE of
0.73±0.11. A TM-SCORE of >0.50 is typically indicative of a correct global fold assignment.
This model was subjected to additional refinement (e.g., sidechain packing and loop refinement)
as described in the methods section above.

110

FIG. 109. Multiple Sequence Alignment illustrating CG4009 aligned against template
structures selected by I-TASSER for multi-template modeling of CG4009.
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2. Validation
The quality of the CG4009 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -6.59). The ProSA per-residue energy score graph is also favorable, showing a score that is
consistently negative over a window size of 40 residues except for loop regions and the N-

Knowledge-based Energy

terminus, which is predicted to be a signal peptide.

Position
FIG. 110. Validation of the CG4009 model: ProQ2 quality score mapped to a 3D model of
CG4009 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
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D. Structural Analyses
A structural superposition reveals that the CG4009 model and the full-length structure of
sheep COX-1 (3N8V) display a similar secondary structure architecture across the modeled
region. Conserved secondary structure elements are readily apparent upon visual inspection of
the superimposed structures, as illustrated by Fig. 113 below. However, the 3D position of many
of these conserved secondary structure elements is shifted in three-dimensional space due to the
alternative placement of intervening loop regions. Thus, while many analogous secondary
structure elements are indeed present when the CG4009 model and COX-1 (3N8V) are
superimposed, the conservation of these elements is not as clear from a pairwise structural
alignment as is the case for many of the other enzymes analyzed in this study.

113

1. Secondary Structure
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FIG. 111. Pairwise alignment of CG4009 and 3N8V generated from structural
superposition with CG4009 with shared secondary structure elements and conserved
residues highlighted.
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2. Physiochemical Properties

FIG. 112. Pairwise alignment of CG4009 and 3N8V generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

PTGS1 (PDB: 3N8V) and CG4009 Model
D. melanogaster
PTGS1 Structure
Superimposed
Model

FIG. 113. PTGS1 (3N8V, cyan-blue) superimposed on the predicted structure of
CG4009 (green-red). RMSD (predicted catalytic domain): 2.660 Å.
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PTGS1 (PDB: 3N8V) and CG4009 Model Superimposed

FIG. 114. PTGS1 (3N8V, cyan-blue) superimposed on the predicted
structure of CG4009 (green-red), with potential matches for conserved
functional residues highlighted.
F. Summary Table
TABLE 17. Templates selected by I-TASSER to model CG4009 using a composite
modeling protocol.

Cyclooxygenase 1
(PTGS1, NP_000953.2,
PDB: 3N8V)

Uncharacterized protein
(CG4009, NP_650588.2)

Length
(AA)

Domain
Architecture
(Pfam, range)

Functional Residues
(aligned matches in
D. melanogaster)

599

Animal heme peroxidase
domain (PF03098)
142-581

H207, Y385 and
H388

649

Animal heme peroxidase
domain (PF03098)
95-617
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H163, Y399, and
H401

Sequence
ID%

Structural
Overlap
(RMSD)

14% ID
26% SIM

2.660 Å

PTGDS
The search for a potential ortholog for PTGDS also proved to be difficult. PTGDS is a
second prostaglandin-D-synthase, which operates in conjunction with the isozyme HPGDS
(discussed above). BLAST-based searching failed to identify any D. melanogaster candidates for
this enzyme (i.e., an apparent ortholog for NP_000945.3). However, iterative HMMER searches
suggested CG33126 (“NLaz,” NP_787960.1) merits further scrutiny despite having only 12%
identity and 31% similarity to PTGDS. Both proteins share similar domain architecture, namely
a Lipocalin (PF00061) domain, which is known to take the form of a beta barrel structure. A
model was generated for PTGDS, as described above. Comparative studies revealed that human
PTGDS (5WY9) and CG33126 overlap with an RMSD 2.084 Å and that CG33126 has an
aligned match for PTGDS’s catalytic cysteine (C65) at position C67. CG33126 contains an Nterminal alpha helix that is absent from PTGDS, however this can helix is predicted to be a
signal peptide. PTGDS contains a similar N-terminal signal peptide that is cleaved during
processing (i.e., omitted from the 5WY9 crystal structure).
A. Secondary Structure Prediction

FIG. 115. Predicted secondary structure of PTGDS and CG33126 calculated using
PROMALS3D.
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B. Domain Architecture

FIG. 116. Predicted domain architecture of PTGDS and CG33126 determined using
Interpro and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG33126. All three tools identify chain A of apolipoprotein D (2HZQ) and chain A of human
prostaglandin D synthase (5WY9) as high-scoring matches suitable for single-template
modeling. 2HZQ and 5WY9 are β-barrel proteins with a substantially similar tertiary structure.
As a result, models generated using either template are substantially similar. For this study,
5WY9 was selected as a template for modeling CG33126.
CG33126 Range
34-184

Template Range
26-178

% Identity
18%

% Similarity
58%

E-Value
5.0e-07

FIG. 117. HMM profile of CG33126 aligned against chain A of 5WY9, a template structure
selected for modeling CG33126.
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2. Validation
The quality of the CG33126 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -5.47). The ProSA per-residue energy score graph is also favorable, showing a score that is

Knowledge-based Energy

largely negative over a window size of 40 residues.

Position
FIG. 118. Validation of the CG33126 model: ProQ2 quality score mapped to a 3D model of
CG33126 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
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D. Structural Analyses
A structural superposition reveals that the CG33126 model and human prostaglandin D
synthase (5WY9) display a similar secondary structure architecture across the modeled region
with substantial full-length overlap. The pairwise alignment generated by this structural
superposition also indicates substantial conservation of residues having similar physiochemical
properties.
1. Secondary Structure

FIG. 119. Pairwise alignment of CG33126 and 5WY9 generated from structural
superposition with CG33126 with shared secondary structure elements and conserved
residues highlighted.
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2. Physiochemical Properties

FIG. 200. Pairwise alignment of CG33126 and 5WY9 generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

PTGDS (PDB: 5WY9) and CG33126 Model
D. melanogaster
PTGDS Structure
Superimposed
Model

FIG. 201. PTGDS (5WY9, cyan-blue) superimposed on the predicted structure of CG33126
(green-red). RMSD: 2.084 Å.

\
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PTGDS (PDB: 5WY9) and CG33126 Model Superimposed

FIG. 202. PTGDS (5WY9, cyan-blue) superimposed on the predicted
structure of CG33126 (green-red), with potential matches for conserved
functional residues highlighted.
F. Summary Table
TABLE 18. Summary of features shared by PTGDS and potential D. melanogaster ortholog
CG33126.

Prostaglandin-D-synthase
(PTGDS, NP_000945.3,
PDB: 5WY9)

Length
(AA)

Domain
Architecture
(Pfam, range)

Functional Residues
(aligned matches in
D. melanogaster)

190

Lipocalin domain
(PF00061)
40-184

C65

Sequence
ID%

12% ID
Neural Lazarillo
(CG33126, NP_787960.1)

224

Lipocalin domain
(PF00061)
48-190

123

31% SIM
C67

Structural
Overlap
(RMSD)

2.084 Å

PTGIS
PTGIS (“prostacyclin synthase”) is another enzyme that does not have a clear ortholog in
D. melanogaster. PTGIS catalyzes the isomerization of PGH2 to prostacyclin, the only
prostaglandin with a bicyclic ring structure. PTGIS encodes a 500 amino acid enzyme
characterized by a cytochrome p450 family domain ranging from position 30 to 494. The Nterminus is predicted to contain a 200 amino acid signal sequence. BLAST and iterative
HMMER searches reveal multiple high-scoring full length matches among the various CYP450
enzymes encoded in the D. melanogaster genome. However, CG3466 (“CYP450-4d2,”
NP_525043.1) was identified as the top candidate based upon similarity of its secondary
structure profile. CG3466 possesses an aligned match for PTGIS’s heme axial ligand (C441) at
position C449. PTGIS (2IAG) and CG3466 are superimposable with an RMSD of 1.213 Å,
despite sharing only 14% identity and 30% similarity at the sequence level.
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A. Secondary Structure Prediction

FIG. 203. Predicted secondary structure of PTGIS and CG3466 calculated using
PROMALS3D.
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B. Domain Architecture

FIG. 204. Predicted domain architecture of PTGIS and CG3466 determined using Interpro
and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG3466. All three tools identify various CYP450 structures as suitable for high confidence
single-template modeling of full-length CG3466. Chain A of human CYP450 3A4 (4DGZ) was a
particularly high-scoring match and selected as a template for generating a model of CG3466 for
this study. Human prostacyclin synthase (2IAG), which is also a member of the CYP450
superfamily, was identified as a template. However, it was indicated as having a lower quality
score for full-length modeling of this target and so was not selected as a template.
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CG3466 Range
31-475

Template Range
18-448

% Identity
32%

% Similarity
57%

E-Value
3.5e-59

FIG. 205. HMM profile of CG3466 aligned against chain A of 4DGZ, a template structure
selected for modeling CG3466.
2. Validation
The quality of the CG3466 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -8.59). The ProSA per-residue energy score graph is also favorable, showing a score that is
substantially negative over a window size of 40 residues except for in a single loop region.
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Knowledge-based Energy

Position
FIG. 206. Validation of the CG3466 model: ProQ2 quality score mapped to a 3D model of
CG3466 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
D. Structural Analyses
A structural superposition reveals that the CG3466 model and human prostacyclin
synthase (2IAG) display a similar secondary structure architecture across the modeled region
with substantial full-length overlap. The pairwise alignment generated by this structural
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superposition also indicates substantial conservation of residues having similar physiochemical
properties.
1. Secondary Structure

FIG. 207. Pairwise alignment of CG3466 and 2IAG generated from structural
superposition with secondary structure elements and conserved residues highlighted.
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2. Physiochemical Properties

FIG. 208. Pairwise alignment of CG3466 and 2IAG generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
E. Analysis of Functional Residues

PTGIS (PDB: 2IAG) and CG3466 Model
D. melanogaster
PTGIS Structure
Superimposed
Model

FIG. 209. PTGIS (2IAG, cyan-blue) superimposed on the predicted structure of
CG3466 (green-red). RMSD: 1.213 Å.
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PTGIS (PDB: 2IAG) and CG3466 Model Superimposed

FIG. 210. PTGIS (2IAG, cyan-blue) superimposed on the predicted
structure of CG3466 (green-red), with potential matches for conserved
functional residues highlighted.
F. Summary Table
TABLE 19. Summary of features shared by PTGIS and potential D. melanogaster ortholog
CG3466.

Prostacyclin synthase
(PTGIS, NP_000952.1,
PDB: 2IAG)
Cytochrome p450-4d2
(CG3466, NP_525043.1)

Length
(AA)

Domain
Architecture
(Pfam, range)

Functional Residues
(aligned matches in
D. melanogaster)

500

Cytochrome p450 family
(PF00067)
30-494

C441

501

Cytochrome p450 family
(PF00067)
31-495
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C449

Sequence
ID%

Structural
Overlap
(RMSD)

14% ID
30% SIM

1.213 Å

LTC4S
Leukotriene C4 synthase (LTC4S), is a 150 amino acid enzyme that catalyzes the
conjugation of leukotriene A4 with reduced glutathione to form leukotriene C4. BLAST searches
against D. melanogaster fail to identify an obvious ortholog. However, an iterative HMMER
search identified the 165 amino acid protein CG33178 (NP_788904.1) as a potential candidate.
The two proteins share full length identity pf 18% and similarity of 31% and have an identical
domain architecture in the form of a single MAPEG domain (PF01124) spanning the bulk of the
protein. Studies of the crystal structure of LTC4S (2PNO) have revealed that it is an integral
membrane protein composed of four transmembrane helices and that it functions as a
homotrimer. The predicted model of CG33178 displays a similar fold, consisting of a bundle of
four alpha helices, and it superimposes on 2PNO with an RMSD of 1.257 Å. CG33178 also
displays potential equivalents for each of LTC4S’s catalytically relevant residues (R30, R31 and
R104) at positions R51, R53 and R139.
A. Secondary Structure Prediction

FIG. 211. Predicted secondary structure of LTC4S and CG33178 calculated using
PROMALS3D.
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B. Domain Architecture

FIG. 212. Predicted domain architecture of LTC4S and CG33178 determined using
Interpro and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG33178. All three tools identify chain A of 2H8A (R. norvegicus Microsomal Glutathione Stransferase 1) as a high-scoring match suitable for single-template modeling. Human leukotriene
C4 synthase is also identified as a potential template, but has a lower full-length alignment score.
CG33178 Range
21-155

Template Range
7-145

% Identity
42%

% Similarity
64%

E-Value
1.0e-24

FIG. 213. HMM profile of CG33178 aligned against chain A of 2H8A, a template structure
selected for modeling CG33178.
2. Validation
The quality of the CG33178 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
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of -4.04). The ProSA per-residue energy score graph is also favorable, showing a score that is

Knowledge-based Energy

consistently negative over a window size of 40 residues except for a single loop region.

Position
FIG. 214. Validation of the CG33178 model: ProQ2 quality score mapped to a 3D model of
CG33178 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
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D. Structural Analyses
A structural superposition reveals that the CG33178 model and human leukotriene C4
synthase (2PNO) display a similar secondary structure architecture across the modeled region
with substantial full-length overlap. The pairwise alignment generated by this structural
superposition also indicates substantial conservation of residues having similar physiochemical
properties.
1. Secondary Structure

FIG. 215. Pairwise alignment of CG33178 and 2PNO generated from structural
superposition with shared secondary structure elements and conserved residues
highlighted.
2. Physiochemical Properties

FIG. 216. Pairwise alignment of CG33178 and 2PNO generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
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E. Analysis of Functional Residues

LTC4S (PDB: 2PNO) and CG33178 Model
D. melanogaster
LTC4S Structure
Superimposed
Model

FIG. 217. LTC4S (2PNO, red) superimposed on the predicted
structure of CG33178 (green). RMSD: 1.257 Å.

LTC4S (PDB: 2PNO) and CG33178 Model Superimposed

FIG. 218. LTC4S (2PNO, cyan-blue) superimposed on the predicted
structure of CG33178 (green-red), with potential matches for conserved
functional residues highlighted.
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F. Summary Table
TABLE 20. Summary of features shared by LTC4S and potential D. melanogaster ortholog
CG33178.
Length
(AA)

Domain
Architecture
(Pfam, range)

Functional Residues
(aligned matches in
D. melanogaster)

150

MAPEG domain
(PF01124)
8-131

R30, R31 and R104

Leukotriene C4 synthase
(LTC4S, NP_665874.1,
PDB: 2PNO)

Uncharacterized protein
(CG33178, NP_788904.1)

165

MAPEG domain
(PF01124)
29-159

Sequence
ID%

Structural
Overlap
(RMSD)

18% ID
31% SIM

1.257 Å

R51, R53 and R139

ALOX5AP
Arachidonate 5-lipoxygenase-activating protein (ALOX5AP, NP_001620.2), the final
target protein in this set, is required for leukotriene synthesis by arachidonate 5-lipoxygenase
(ALOX5). It has been reported that ALOX5AP functions by binding ALOX5 to the membrane
and loading polyunsaturated fatty acid substrates (e.g., arachidonic acid) onto ALOX5 for
conversion into leukotriene A4. Like LTC4S above, ALOX5AP is a MAPEG family protein that
functions as a membrane-associated homotrimer. BLAST searches for a potential ortholog do not
identify a clear match in D. melanogaster, though iterative HMMER searches reveal CG33177
and CG33178 as potential candidates. Both are MAPEG family proteins with highly similar
sequences and predicted tertiary structures. CG33178 displays greater sequential similarity to
LTC4S and analogs for the catalytically relevant residues and so was assigned as the top
candidate for LTC4S. As a result, CG33177 was selected as the top candidate for a potential
ortholog for ALOX5AP. The two proteins display 13% identity and 28% similarity and overlap
with an RMSD of 1.024 Å.
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A. Secondary Structure Prediction

FIG. 219. Predicted secondary structure of ALOX5AP and CG33177 calculated using
PROMALS3D.
B. Domain Architecture

FIG. 220. Predicted domain architecture of ALOX5AP and CG33177 determined using
Interpro and Pfam.
C. Model Generation and Validation
1. Generation
HHpred, Phyre2 and LOMETS were used to identify suitable templates for modeling
CG33177. All three tools identify chain A of 2H8A (R. norvegicus Microsomal Glutathione Stransferase 1) as a high-scoring match suitable for single-template modeling.
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CG33177 Range
23-156

Template Range
8-144

% Identity
44%

% Similarity
63%

E-Value
7.8e-28

FIG. 221. HMM profile of CG33177 aligned against chain A of 2H8A, a template structure
selected for modeling CG33177.
2. Validation
The quality of the CG33177 model was evaluated using ProQ2 and ProSA, as described
above in the discussion of CG1742. Again, overall model quality is high (a ProSA global Z-score
of -4.33). The ProSA per-residue energy score graph is also favorable, showing a score that is
consistently negative over a window size of 40 residues, except for the flexible C-terminal αhelix.
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Knowledge-based Energy

Position
FIG. 222. Validation of the CG33177 model: ProQ2 quality score mapped to a 3D model of
CG33177 (top); ProSA global quality score ranking (lower left) and per-residue quality
graph (lower right).
D. Structural Analyses
A structural superposition reveals that the CG33177 model and human ALOX5AP
(2Q7M) display a similar secondary structure architecture across the modeled region with fulllength overlap. The pairwise alignment generated by this structural superposition also indicates
substantial conservation of residues having similar physiochemical properties.
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1. Secondary Structure

FIG. 223. Pairwise alignment of CG33177 and 2Q7M generated from structural
superposition with shared secondary structure elements and conserved residues
highlighted.
2. Physiochemical Properties

FIG. 224. Pairwise alignment of CG33177 and 2Q7M generated from structural
superposition with conserved residues highlighted using the CLUSTALX color scheme.
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E. Analysis of Functional Residues

ALOX5AP (PDB: 2Q7M) and CG33177 Model
ALOX5AP
D. melanogaster
Superimposed
Structure
Model

FIG. 225. ALOX5AP (2Q7M, cyan) superimposed on the predicted
structure of CG33177 (green). RMSD: 1.024 Å.

ALOX5AP (PDB: 2Q7M) and CG33177 Model Superimposed

FIG. 226. ALOX5AP (2Q7M, cyan-blue) superimposed on the predicted
structure of CG33177 (green-red), with potential matches for conserved
functional residues highlighted.
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F. Summary Table
TABLE 21. Summary of features shared by ALOX5AP and potential D. melanogaster
ortholog CG33177.

Arachidonate 5-lipoxygenaseactivating protein
(ALOX5AP, NP_001620.2,
PDB: 2Q7M)

Uncharacterized protein
CG33177, NP_788903.1)

Length
(AA)

Domain
Architecture
(Pfam, range)

Functional Residues
(aligned matches in
D. melanogaster)

161

MAPEG domain
(PF01124)
5-136

N/A

167

MAPEG domain
(PF01124)
30-161

143

Sequence
ID%

13% ID
28% SIM
N/A

Structural
Overlap
(RMSD)

1.024 Å

Chapter 4. Discussion
Our results suggest that D. melanogaster may possess a set of eicosanoid synthesis
enzymes similar to the canonical eicosanoid synthesis enzymes found in humans and mammals
generally. At this stage, it is unknown whether these enzymes form a functional eicosanoid
synthesis pathway similar to the mammalian pathway or if D. melanogaster possesses a unique
eicosanoid synthesis pathway (e.g., structural differences in the D. melanogaster enzymes may
result in the processing of different PUFA substrates and synthesis of alternative lipid mediators
other than the canonical eicosanoids). Notwithstanding these caveats, a schematic of a putative
D. melanogaster eicosanoid synthesis pathway based on our analysis is shown as Fig. 227 below.
Notably, the proposed pathway appears to account for a full complement of prostaglandin
synthesis enzymes. A functional thromboxane synthesis pathway may also be present, as
potential orthologs for thromboxane A synthase have been identified. However, given the
structural and sequential similarity of TBXA synthase to the numerous functionally unrelated
cytochrome p450 oxidase in the D. melanogaster genome, speculation must be reserved pending
experimental validation. The existence of a leukotriene synthesis arm of the pathway could not
be fully resolved since a thorough search of the D. melanogaster genome has failed to identify a
potential lipoxygenase, which is critical for the initial processing of the PUFA substrate into
leukotriene intermediates. Interestingly, potential orthologs exist for each of the downstream
leukotriene processing enzymes. Based upon our current understanding, a functional
lipoxygenase is necessary for HETE intermediates and the corresponding final products (e.g.,
lipoxins and other non-canonical eicosanoids).
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FIG 227. A theoretical D. melanogaster eicosanoid synthesis pathway.
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Studies using conventional sequence analysis techniques alone have failed to demonstrate
the possible existence of a functional eicosanoid synthesis pathway and these negative results
suggested that flies do not possess the ability to synthesize eicosanoids [105, 106]. However, our
data challenges this view and suggest that the fly genome may in fact possess potential orthologs
for a majority of the eicosanoid synthesis enzymes. These candidates have thus far eluded
detection because of the high degree of sequential divergence compared to the mammalian
enzymes. However, when compared at the structural level it is clear that these candidates share
the same overall fold and matches for the known or predicted catalytic residues. The existence of
eicosanoid synthesis enzymes would partially explain recent studies that have identified
prostaglandins or prostaglandin-like compounds in D. melanogaster when AA was provided in
their diet [106-108]. However, questions remain as to the exact role played by these enzymes and
the intermediate and final end products of the pathway.
We speculate that the apparently missing lipoxygenase may be partially explained by D.
melanogaster expressing a cyclooxygenase with lipoxygenase activity. Dual functional
cyclooxygenases have been identified which are able to generate prostaglandins and
lipoxygenase products (e.g. HPETEs). For example, mammalian cyclooxygenases have been
shown to produce limited amounts of 11- and 15-HPETE as a by-product in addition to PGH,
[109-112], and aspirin-acetylated COX-2 has been shown to produce 15R-HETEs [113]. Similar
activity by one of the putative D. melanogaster COX orthologs could provide upstream
processing needed for 11- and 15-HPETE, though this fails to provide the 5-HPETE intermediate
needed for downstream leukotriene synthesis. Alternatively, 5-HETEs may be produced using an
unconventional mechanism by the COX candidates or perhaps by an unidentified enzyme. The
existence of structurally conserved downstream leukotriene synthesis enzymes suggests that the
upstream intermediates are likely present in some form. D. melanogaster may possess a CYP450
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enzyme capable of synthesizing 5-HETE; lipoxygenase-like CYP450s have been identified that
produce 5-, 8-, 9-, 11-, 12- and 20-HETEs [114, 115]. Recent studies have reported on bacterial
lipoxygenases which are highly divergent from animal and plant lipoxygenases, both in terms of
overall sequence conservation and the presence of expected catalytic residues [116]. There is
also a possibility that D. melanogaster expresses a functional 5-LOX that radically differs from
the canonical profile of a lipoxygenase.
The existence of a functional eicosanoid synthesis pathway requires both the presence of
the requisite synthetic enzymes and suitable substrates. The mammalian eicosanoids are
primarily derived from 20-carbon PUFAs (arachidonic acid, eicosapentaenoic acid and dihomoγ-linolenic acid), as well as from 18-carbon PUFAs (γ-linolenic acid, α-linolenic acid and
linoleic acid). It has been reported that the D. melanogaster lacks homologs for the mammalian
Δ5 and Δ6 desaturases based upon sequence analyses, and so it should be unable to synthesize
20–22 carbon PUFAs from essential fatty acid precursors [117]. Studies by the same group have
also shown that flies raised in the absence of 20-carbon PUFAs for several generations remain
healthy, implying that 20-carbon PUFAs are non-essential [106]. Based on these findings it is
generally accepted that D. melanogaster relies on PUFAs obtained from its vegetarian diet,
which is generally limited to the essential 18-carbon fatty acids linoleic acid (18:2n-6) and αlinolenic acid (18:3n-3).
In the vertebrate pathway, the 18-carbon fatty acids linoleic acid and α-linolenic acid can
be processed into the 20-carbon PUFAs arachidonic acid and eicosapentaenoic acid,
respectively, via a three-step process. First, a double bond is removed by a Δ6 desaturase and
then an elongase extends the PUFA chain by the addition of two carbons. Finally, a Δ5
desaturase removes a double bond, completing the conversion. These 20-carbon PUFAs are then
capable of being processed by COX or LOX to generate the canonical eicosanoids. 18-carbon
147

PUFAs (e.g., linoleic acid) may also be processed by 15-LOX into hydroxyoctadecadienoic acids
(9- and 13-HODEs), a subfamily of non-canonical eicosanoids. Based on the current
understanding that D. melanogaster lacks Δ5 and Δ6 desaturase activity, it would be expected
that the 18-carbon PUFAs obtained from its diet are processed into HODEs as opposed to
eicosanoid derivatives of the 20-carbon PUFAs. Recent studies have validated this hypothesis,
confirmed the presence of 9- and 13-HODEs in D. melanogaster extracts [118]. However, given
the reports of prostaglandin-like molecules in D. melanogaster extracts, it is probable that
additional lipid processing is taking place to produce compounds similar to the canonical
eicosanoids. Contrary to the published literature, our HMMER-based sequence analysis of the D.
melanogaster genome has identified a potential Δ5 and Δ6 desaturase which is not identified by
typical BLAST searches. The uncharacterized genes CG17928 and CG13279 (NP_609810.1 and
NP_477154.1, respectively) encode proteins with reasonable full-length alignment to the human
Δ5 and Δ6 desaturase. These D. melanogaster proteins display domain architecture similar to the
human enzymes and possess the critical His box 1, 2 and 3 motifs essential for desaturase
activity [119]. Based on these findings, we suggest that D. melanogaster may in fact have a
mechanism of converting C18 to C20 PUFAs. The existence of this functionality and the nature
and extent of expression of these putative desaturases will need to be experimentally validated,
though biochemical evidence may be difficult to obtain if expression is occurring at a low level
or in a limited population of tissue. Most of the biochemical studies reporting prostaglandin-like
compounds in D. melanogaster have identified these compounds in a limited subset of tissue
(e.g., in reproductive tissue during oogenesis) [120]. However, based on our findings it appears
that the existence of Δ5 and Δ6 desaturases cannot be conclusively ruled out at this time.
The present study suggests that D. melanogaster has a set of eicosanoid synthesis
enzymes, and in fact may possess a functional equivalent for the mammalian eicosanoid
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synthesis pathway. Due to the limitations of traditional sequence analysis techniques we have
explored advanced approaches to identify orthologs and demonstrate that structural models
generated for several of these distant matches appear to display a high degree of structural
similarity with members of the mammalian eicosanoid synthesis pathway and possess putative
analogs for known functional residues. These initial findings, combined with other recent
biochemical studies, suggest the possibility that D. melanogaster likely utilizes of eicosanoid
signaling, raising the possibility that it may be useful as a model for the study of eicosanoid
signaling and inflammation. Our studies with Drosophila, a system with low genetic redundancy
and remarkable biological conservation will be highly relevant and transferrable to designing
therapies for chronic disorders in humans. Our findings will also be relevant to the development
of novel insect control measures.
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